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ABSTRACT 
The goal of translational research is to improve public health by accelerating basic 
science discovery to human application and clinical practice.  The NHLBI Bench-to-Bassinet 
(B2B) program promotes this goal through its translational research initiative.  Together with 
other collaborators of the B2B program, the University of Pittsburgh mutagenesis screen strives 
to elucidate the underlying genetic and developmental processes of congenital heart disease 
(CHD), which is a significant source of morbidity and mortality in the population.  The screen 
investigators have curated over 200 mouse models of CHD on the Jackson Laboratory (JAX) 
Mouse Genome Database (MGD) through a multi-tiered strategy of phenotypic and genetic 
analyses.  Within the translational research paradigm, this screen has contributed to the 
improvement of public health and patient care by enabling the identification of 107 pathogenic 
mutations in 68 unique genes as well as providing 62 models of human disease for future 
research and development of therapies.  Two mutant mouse lines, lines 1702 and 2407, will be 
thoroughly discussed with regard to their significance to research.  However, analysis of the 
screen curation protocol demonstrated inefficiencies representative of problems across the 
entirety of the translational research continuum.  Within this continuum, data must be translated 
and readily shared between databases in each domain.  Research is currently scattered across 
disconnected, autonomous databases, which prevents data integration and comprehensive 
retrieval of information from a single platform.  Moreover, data are represented as a combination 
of discordant ontologies and free-text annotations, which further impede cross-species or cross-
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domain comparisons and database integration.  Although ontology mapping endeavors have 
achieved some success, the process is flawed with unequivocal alignments or inaccuracies and 
requires extensive manual validation.  Harmonization of ontologies through, ideally, a 
standardized, relational framework, is necessary to improve the efficacy and utility of 
translational research.  In summary, the future progress of translational research, as exemplified 
by the University of Pittsburgh B2B program, and its potential in improving public health 
depends on the acceleration of basic discovery to clinical application through a network of 
integrated databases supported by a unified ontological system. 
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PREFACE 
A major challenge in congenital heart disease (CHD) translational research is the coding of 
phenotype data to permit meaningful translation of phenotype descriptions between model 
organisms and human diseases, e.g. between mouse and human.  Accurate and efficient 
translation will facilitate phenotype-driven gene function discovery and empower comparative 
pathophysiology in CHD research.  Success in the Human Genome Project (HGP) and 
advancements in technical methodologies, such as next generation sequencing (NGS) and large-
scale mutagenesis screens—have provided new insights into the underlying pathways, genotype-
phenotype correlations, and genetic etiologies of human diseases.  Whereas bottlenecks once 
existed in the generation of model organisms and genetic profiles, today the chokepoints of 
translational research exist due to limitations in analysis as well as informal annotation of the 
associated phenotypes.   
To best exploit emerging mouse phenotype data, it must first be described at high-
resolution and -specificity in order to distinguish between closely-related phenotypes as well as 
identify patterns suggestive of a common etiology.  This growing wealth of species-specific 
information must be systematically coded in a way that is tractable to computational analysis.  
Standardization of data is necessary in order to preserve its integrity and to support future 
research.  Biomedical databases can mine and aggregate immense volumes of data in order to 
identify novel models of interest as well as gene-gene or gene-phenotype relationships.  Through 
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databases, ongoing CHD research can be more easily integrated with both current and pre-
existing research.  Ultimately, this would improve human health care by promoting the 
translation of basic biomedical science discoveries to its application in clinical practice and 
patient care. 
Currently, databases are isolated within its respective domains, which is, in part, a 
consequence of the ontology upon which the databases is based.  The biomedical and 
bioinformatics communities are developing formalized and standardized methodologies for 
phenotype annotation within ontologies so as to improve database interoperability and 
translational research application. Ontology-based database searches can retrieve comprehensive 
and relevant information that is amenable for comparative analysis and elucidation of underlying 
relationships.   Individually, an ontology is precisely structured and enhances data annotation, 
but as a group, these qualities are the contributing factors of its incompatibility.  Mapping 
ontologies will be increasingly necessary to promote data integration and collaboration.  A 
reference ontology can provide the relational framework for future mapping projects.  
The goals of this thesis are to analyze the ongoing CHD mutagenesis screen protocol, in 
particular the translation of its phenotypic data, at the University of Pittsburgh and its role in the 
NHLBI B2B program.  It will focus on the significance of accurate curation within the 
translational research paradigm and ultimately, its potential in patient care, including 
interpretation of genetic variation, counseling of CHD recurrence risks, and identifying novel 
model organisms for the development of new drugs or therapies.  This analysis will exemplify 
the need for a standardized phenotype annotation, consistent ontology design, coherent database 
integration, and collaboration.  Reference tables of acronyms and abbreviations used throughout 
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the dissertation can be found in Appendix C.  Revisions to the current curation protocol for the 
collection and annotation of CHD phenotypes will be proposed.  
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1.0  INTRODUCTION 
Phenotype can be defined as the observable traits of an organism in a given environment1,2.  An 
organism’s traits are its heritable features, such as “eye color” or “tail length,” which are not 
influenced by the environment1.  Whereas a trait is the observable and measureable expression of 
genes, a phenotype describes the variable quality of a trait, e.g. “blue eyes” or “short tail”1,3.  
Properties of a phenotype may comprise of the physiological, morphological, as well as 
behavioral aspects of the organism and frequently in relation to its deviation from normal, i.e. 
phenodeviance1,4.  The sum of all traits and relationships that exist between genes and phenotype 
is called a phenome1,5,6. 
Phenogenomics is the elucidation of the functional human genome through discoveries 
based on the meticulous, comparative analysis of disease phenotypes7,8.  Deep phenotyping, or 
the precise description and examination of a phenotype as well as all its individual components 
within the spectrum, can provide the high-resolution level of phenotypic data necessary for 
successful phenogenomics1,9.  Ideally, annotation of observed phenotypes by deep phenotyping 
is systemically coded into complementary ontologies.  Ontologies are conceptual representations 
of a particular domain in which its granular entities are linked by hierarchical, semantic 
relationships1,10–12.  Semantic relationships refer to both the degree of relatedness of each entity’s 
formal definition—as defined by the ontology and measured as semantic similarity—as well as 
specificity in the overall ontological schema13–15.  Ontologies, by design, are exclusively 
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specialized.  Consequently, it is difficult to map two ontologies together for cross-species 
comparison and data translation.   
Ontology incompatibility impedes the integration of databases and as a result, the 
valuable data it contains, which further contributes to the pervasive deficiency in the application 
of relevant knowledge to clinical research and practice.  Of the interest for this thesis, is the 
translation of congenital heart disease (CHD) phenotype studies in mouse models to publically 
accessible data repositories within an innovative bench-to-bassinet continuum.   
1.1 CONGENITAL HEART DISEASE 
Congenital heart disease (CHD), as defined by Mitchell et al.16, is “a gross structural abnormality 
of the heart or intrathoracic great vessels [resulting from abnormal development of its structural 
parts] that is actually or potentially of functional significance.”  CHD occurs in about 1% of live 
births in the United States and only 40% of these infants are diagnosed within their first year of 
life17–20.  Incidence may be as high as 5% if commonly excluded defects, such as bicuspid aortic 
valve, isolated aneurysm of atrial septum, and persistent left superior vena cava, are included17,18.  
About 40,000 infants are born each year with CHD, and of these, about a third have complex 
defects, which require medication and/or surgery21,22.  CHD is undoubtedly a public health 
concern. 
Moreover, CHD is associated with significant mortality.  It is currently the leading cause 
(about 30%) of infant mortality, or death from age 28 days to one year, due to birth defects22.  
Although the development of new treatments and diagnostic protocols—including the 
introduction of cardiopulmonary bypass in the 1950’s and the Fontan procedure in the 1970’s—
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have improved the survival rate of individuals with CHD, across all instances of infant mortality 
from 1987 to 2006, at least 10% involve CHD with 66% of those deaths either directly related to 
CHD or its treatment23.  To continue improving CHD survival rates, the U.S. Department of 
Health and Human Services (HHS) Secretary approved newborn screening for CHD in 
September 201124.  Newborn screening allows earlier detection and subsequent treatment of life-
threatening CHD by measurement of blood oxygen saturation, e.g. pulse oximetry24.  Pulse 
oximetry may detect about a quarter of all CHD, namely hypoplastic left heart syndrome 
(HLHS), pulmonary atresia (PA, with intact septum), tetralogy of Fallot (TOF), total anomalous 
pulmonary venous return (TAPVR), transposition of the great arteries (TGA), tricuspid atresia, 
and truncus arteriosus22.  
CHD is generally classified into three categories based on clinical significance and 
structural involvement: [1] severe or critical, [2] moderate, and [3] mild17,24.  [1] Severe CHD is 
often a life-threatening structural malformation that can be either cyanotic, e.g. results in low 
blood oxygen levels, such as D-loop TGA, TOF, HLHS, and double outlet right ventricle 
(DORV), or acyanotic, such as atrioventricular septal defects (AVSD) and severe aortic (AS) or 
pulmonary stenosis (PS)17,24.  A severe CHD is considered critical if the defect requires surgery 
or a catheter-based intervention in the first year of life; critical CHD accounts for approximately 
25% of all CHD22.  [2] Moderate CHD has clinical significance and includes noncritical 
coarctation as well as complex forms of ventricular septal defects (VSD)17,24.  VSDs are the most 
common type of CHD16,17,19,25. [3] Mild CHD—such as small VSD or patent ductus artiousus 
(PDA)— are asymptomatic and frequently resolve spontaneously22,24.   
CHD may occur as an isolated case, as part of a syndrome, or as a feature in a collection 
of multiple congenital anomalies, including dysmorphic facies, limb and skeletal abnormalities, 
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as well as organ malformations.  More importantly, CHD can serve as a significant indicator of 
an underlying genetic defect or syndrome.  For instance, in many familial cases of 22q11.2 
deletion syndrome, which is a highly variable genetic condition, only after the child with CHD is 
diagnosed with 22q11.2 deletion syndrome, is one of the parents found to have the deletion and 
with subtle features26.  Furthermore, in a clinical setting, cytogenetic testing and chromosome 
analysis are regularly considered if a CHD is detected on ultrasound or echocardiogram due to 
the common presentation of CHD with genetic defects. 
1.1.1 Genetics of CHD 
CHD is a genetically heterogeneous developmental disruption that exhibits variable expressivity 
and reduced penetrance18,27,28.  The majority of CHD occurs as sporadic or isolated cases with a 
multifactorial etiology consisting of a combination of genetic, environmental, and/or teratogenic 
factors27,29.  The phenotypic variability seen in CHD may result from genetic modifiers, the 
interaction of multiple genes, combination of genetic and environmental factors, and/or 
stochastic effects23,30.  Although there is little known about the specific gene defects contributing 
to a particular CHD phenotype, the genetic contributions to CHD development have been 
established.  For instance, single gene defects, such as those affecting NKX2.531,32, JAG133, 
GATA434–36, and NOTCH137, have been identified in both clinical and research studies of 
nonsyndromic CHD.  Moreover, individuals with a CHD have a higher risk of having a child 
with a CHD than individuals without a CHD: 3.1% and 1.3%, respectively, as well as a 
significant odds ratio of 1.73 between patients and controls29,30,38.  Some CHDs, such as atrial 
septal defect (ASD) and PDA, have also demonstrated Mendelian inheritance18,30.  These 
findings suggest that a significant component in the etiology of CHD is genetic.   
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As mentioned above, CHD may occur as part of a syndrome and correlated with 
particular genes, including 22q11.2 deletion (TBX1)39,40, Williams-Beuren (WBS)41,42, Alagille 
(JAG1)43, Noonan (PTPN11, KRAS, SOS1)44,45, and Holt-Oram (TBX5)46.  The phenotypic 
spectrum of CHD associated within these syndromes, however, is broad, ranging from PS to 
TOF.  Furthermore, at least 30% of children with chromosomal abnormalities or alterations—
including aneuploidies trisomy 21, trisomy 13, trisomy 18, and Turner syndrome—have 
CHD18,25,47.  One or more genes may be contributing to the development of CHD, particularly in 
chromosome conditions or structural anomalies where multiple genes are affected.  As CHDs are 
often part of a syndrome, attributing the genetic etiology of one developmental process may have 
implications on others.  Genotype-phenotype correlations will play an important role in 
elucidating the underlying pathobiology of CHD as well as the short- and long-term care of these 
patients.   
It is clear that for effective clinical management and counseling we need to improve our 
understanding in the genetics of CHD.  In the clinical setting, identifying an underlying genetic 
pattern could have vital implications in the other organ systems as well as the patient’s 
prognosis, reproductive risks, and at-risk family members who may also benefit from testing and 
intervention18.  As CHD has highly variable expressivity, comprehensive assessment is necessary 
both of the individual and their family.  Evaluations may extend to non-cardiac structures, such 
as the liver and skeleton in Alagille Syndrome or the palate in 22q11.2 deletion syndrome, if the 
CHD is syndromic or associated with a known phenotype.  
Understanding the genetics of CHD will provide insight on the biological pathways 
responsible for cardiac morphogenesis and its interactions with the development of other organs 
and systems.  Although numerous pathways and components involved in the development of the 
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cardiovascular system have been identified, much is unknown.  There is a growing clinical need 
to improve healthcare and treatment for patients with CHD, and as clinical need drives research 
focus, there is a reciprocal demand for further basic science studies and collaborative 
translational research efforts.   
1.2 DEVELOPMENTS IN TRANSLATIONAL RESEARCH 
Translational research, or research that progresses from bench to bedside, is the movement of 
discoveries from basic science to human research then to clinical practice before returning to the 
laboratory in order to direct further research.  Whereas basic science aims to better understand a 
disease and its development, clinical research is patient-oriented and involves epidemiologic or 
behavioral studies, as well as investigations into prognostic outcomes and health services.  Both 
are necessary to improve public health because although discoveries made in basic research can 
be applied to answer a number of clinical problems, it is itself insufficient to answer the question 
completely.  Similarly, the laboratory permits practical and ethical allowances that are prohibited 
in human clinical research.   
Translational research originates from a health need that drives the direction of basic 
research to ultimately promote better identification, treatment, and prevention of that health 
need.  As more knowledge and evidence accumulates in one domain, hypotheses are generated, 
translated, and tested in the next.  The data gathered in the laboratory provides a foundation for 
patient research and trials.  The results of these clinical studies will then either modify the 
original question or identify a new health need and the cycle repeats.   
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In the past two decades, major accomplishments in the field of biomedical and 
computational sciences have accelerated the development of translational research. Rapid 
advances in sequencing technologies, notably next generation sequencing (NGS), have produced 
the comprehensive characterization of the human genome with the Human Genome Project 
(HGP) as well as the mouse genome.  The cost for first sequenced human genome was over $3 
billion, but today it has dropped dramatically to less than $4,000 (extracted from 
http://www.genome.gov/sequencingcosts/).  In the near future, whole genome sequencing may 
replace many laboratory tests.  NGS has provided researchers the technology for cross-species 
comparisons such that discoveries in one organism may be readily bridged to another.  The use 
of animal models allows experimental investigation, manipulation, and testing of specific 
hypotheses in a controlled environment—all of which is more limited or not feasible with human 
subjects. 
1.2.1 Goals of Translational Research 
The overall purpose of translational research is to improve both individual and public health by 
applying novel discoveries on the mechanisms of disease in order to develop new or improved 
strategies for patient care of that disease.  It attempts to close the phenotype-genotype gap in 
disease that hinders breakthroughs in understanding the phenotypic manifestations of genetic 
defects.  There are obstacles, however, to the translation of data from one domain (e.g. mouse) to 
another (e.g. human). Translation converts the representation of data in one system to its 
equivalent in another with minimal interruption or distortion of the original. 
According to the Institute of Medicine Clinical Research Roundtable (IMCRR), there are 
two blocks (gray boxes) in the translational continuum as depicted below in Figure 1.2.148,49.  
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These obstacles to the translational research continuum (red box) include a rigid infrastructure 
with static or unidirectional communication, lack of standardized methods for data analysis and 
annotation, incompatible databases, small sample size, fragmented infrastructure, lack of 
qualified investigators, as well as financial obstacles such as high research costs and lack of 
funding48,49.  The first block (T1) occurs between translation of basic science discovery in the 
laboratory (i.e. bench, blue) to human clinical research (i.e. bedside, yellow); it primarily affects 
the development of better diagnosis, treatment, and prevention in patients48.  The second block 
(T2) occurs during practice-based research and impedes the translation of results from clinical 
studies (i.e. bedside, yellow) into standard clinical care (i.e. policy and practice, green).  T2 may 
be divided into two sub-blocks: the first affects translation from clinical research to patients 
while the second affects translation to policy and practice from patient-based research.  Figure 
1.2.1 was amended to incorporate the objectives of the National Heart, Lung, and Blood Institute 
(NHLBI) Bench to Bassinet (B2B) Program within its respective consortia, the Cardiovascular 
Development Consortium (CvDC) and Pediatric Cardiac Genomics Consortium (PCGC).  The 
program also coordinates with the Pediatric Heart Network (PHN), which is representative as the 
clinical practice and application domain in Figure 1.2.1.  The B2B program is discussed in more 
detail in Section 2.1.   
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Figure 1.2.1.  Translational blocks (gray) in the B2B continuum  (adapted from Sung et al.48) 
 
The translational blocks in Figure 1.2.1 are in part addressed by the growing popularity of 
translational research programs, such as B2B, specifically designed to overcome these 
challenges.  National, government-funded programs promote consortium-wide collaborations 
from multiple levels in the biomedical continuum in order to foster the advancement of 
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translation of from basic to clinical study by facilitating dynamic communication, access to a 
larger recruitment population, as well as opportunities to partner with experts in other fields.  
The translational blocks most resolved by these multi-disciplinary consortia are denoted with an 
asterisk (*) in Figure 1.2.1.  
1.2.2 Mouse Models of Human Disease 
Laboratory mice (Mus musculus) have been used extensively in many fields of biomedical 
research due to its many advantages, e.g. cheap maintenance, small size, and amenability to 
various manipulations.  Mice are also prolific breeders with a large litter size and have an 
accelerated life-span compared to humans.  Furthermore, compared to humans, mice have 
similar anatomies, physiologies, and genetics; its genome and physiology are also well 
characterized.  Developmentally, one mouse year is equivalent to about thirty human years.  
Therefore, mouse models readily enable the study of a human disease at nearly every age.  
Moreover, mice can be genetically manipulated, via transgenic, knockout, and mutagenesis 
techniques, which makes it an ideal animal model for translational research.   
Over 95% of the mouse genome (23,148 protein-coding genes on 21 chromosomes) is 
similar to the human genome with much of the physiology and gene function well conserved 
between the two species (extracted from http://useast.ensembl.org/)7.  Conservation of gene 
function across species is demonstrated by similar phenotype manifestations of loss-of-function 
mutations in orthologous genes50.  The production and utilization of mouse models of disease has 
exponentially increased with the recent advancement of forward and reverse genetic techniques.  
Currently, there are 17,054 protein-coding mouse genes with an identified ortholog in humans, 
4,348 mouse genotypes modeling human diseases, and 1,307 human diseases with at least one 
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mouse model (extracted from 
http://www.informatics.jax.org/mgihome/homepages/stats/all_stats.shtml).  
In relationship to CHD research, the complex pathways involved in the morphogenesis of 
the mouse heart are similar to those of the human heart36,51,52.  Both mouse and human hearts are 
four-chambered structures with two outflows and distinct left-right asymmetries required to 
separate pulmonary and systemic circulation, which is essential for oxygenation of blood36,51,52.  
This structural and developmental similarity, coupled with advantages of using mice to study 
human diseases mentioned above, allows for the generation of specialized mouse models that 
represent phenotypes at stages and ages most relevant for human CHD.  It is important to 
remember, however, that not all mouse genes—and its molecular functions—have an 
orthologous human counterpart and therefore not all mouse models are representative of human 
diseases.  
1.2.3 Forward and Reverse Genetics 
There are two major strategies for developing mouse models for a specific interest: forward and 
reverse genetics.  Both strategies aim to connect gene with function and subsequently, its role in 
the pathways and development of a particular phenotype/disease.  Reverse genetics is a 
genotype-driven approach as a target gene is first modified and then the resulting phenotype is 
analyzed8.  Common reverse genetics methodologies include knockout/in mice via gene-
targeting technology and gene trapping to produce gene-specific mutations.  The International 
Knockout Consortium (IKMC) is currently utilizing gene-targeting and gene traps with the goal 
of creating a knockout strain for every gene in the mouse genome.  The International Mouse 
Phenotyping Consortium (IMPC) aims to phenotype, in high resolution, 20,000 IKMC mutant 
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lines in order to determine the biological function of each gene.  Transgenic and knockout mouse 
models have demonstrated the effectiveness of mouse as a model animal for human CHD53–56.  
Transgenic and knockout mice, however, are limited to analysis of one gene at a time and are 
vulnerable to bias due to a-priori candidate gene hypotheses.   
In contrast, forward genetics, such as mutagenesis screens—namely those utilizing N-
ethyl-N-nitrosurea (ENU)—allow a genome-wide scan for candidate genes that may play a role 
in a pre-defined phenotype of interest8,57.  Forward genetics is also known as the phenotype-
driven approach and is dependent on validated phenotyping resources and modalities.  Compared 
to the reverse genetics approach, it can rapidly generate multiple inbred mice strains with each 
harboring numerous random mutations across its genome.  Notably, a single point mutation with 
a specific phenotypic effect resulting from ENU treatment occurs every 500-1000 mouse 
gametes tested57.  With focused and precise phenotyping of many mice in a single breeding 
line—therefore reducing the confounding effects of genetic heterogeneity—, novel gene 
discovery can be greatly accelerated.  Gene-driven and phenotype-driven strategies in reverse 
and forward genetics, respectively, are illustrated in Figure 1.2.37. 
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Figure 1.2.3. Different approaches in forward and reverse genetics (adapted from Kim et al.7) 
1.2.3.1 High-Throughput Techniques 
Prior to the Human Genome Project (HGP), there were bottlenecks in translational 
research that impeded the phenotypic and genetic characterization of human disease.   These 
bottlenecks had largely consisted of the genotyping, physical mapping, and sequencing of 
molecular data7,58.  HGP coupled with the advancement in high-throughput technology such as 
microarrays, NGS, as well as mutagenesis screens, have shifted these technical bottlenecks to 
new bottlenecks of phenotype analysis, including phenotype annotation, and data integration as 
illustrated in Figure 1.2.3.17,58.  Figure 1.2.3.1 depicts the bottlenecks (red) (a) prior to 
technological advancement and the success of the HGP and (b) its current status within a 
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selected portion of the translational continuum. New methodologies are needed to address these 
latest challenges in phenotype analysis and data integration in order for translational research to 
progress. 
 
Figure 1.2.3.1. Bottlenecks (red) in translational continuum (a) prior to and (b) after HGP and high-throughput 
technologies (adapted from Biesecker et al.58) 
1.2.4 Deep Phenotyping 
Deep phenotyping, if performed systematically with high resolution and specificity, can improve 
the exploitation of mouse mutagenesis screens by identifying models for human disease as well 
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as novel insights into the diseases itself9,11.  Imprecise phenotyping can have detrimental effects 
on the subsequent exploration of the data, including genotype-phenotype correlations and 
phenogenomics.  Incomplete phenotyping, which can be circumvented by standard protocols for 
phenotype annotation, will diminish the potential power of model organisms of disease.  Better 
formulated and thorough annotation of phenotypes will improve the accuracy to which 
phenotype similarity or overlap across databases reflect related pathophysiology5.   
The applications of deep phenotyping include comparative analysis of disease between 
associated phenotypes as well as integration into genome browsers or phenotype databases to 
add relevant data, such as feature frequency9,11.  The underlying genetic networks and pathways 
of new diseases may also be uncovered by examining patterns of observed phenotypes and 
correlations with specific genetic profiles.  Phenotypic overlap can be a good predictor of a 
common genetic pathway and indicate a syndrome family5,59.  For instance, ciliopathies result 
from mutations in genes involved in ciliary function, but have a wide range of phenotypic results 
from laterality defects to retinopathy to kidney cysts and can interact at the molecular level of 
overlapping syndromes, e.g. nephronophthisis, Joubert syndrome, Leber congenital amaurosis, 
and Meckel Syndrome5,6,47.  This has facilitated the identification of ciliary diseases as well as of 
novel ciliopathy genes.   
In addition, deep phenotyping can establish relationships between gene function and 
phenotype, of which one component is associated with several genes in the same pathway.  This 
could provide a mechanism to more rapid identification of candidate genes as well as other 
models of human disease either within the same species or in another.  As insights on a particular 
biological disease or processes mature, it will be feasible to screen for mutations and genes that 
modify existing or well-characterized phenotypes.  
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 As the number of large-scale phenotyping projects increases, it becomes imperative to 
develop semantic and technical standards for phenotype and disease data descriptors, particularly 
in databases for correlating model organism phenotypes with genomic variation.   Systematic 
terminology is required as commonly used free-text descriptions may suggest a different 
message to different readers, depending on individual knowledge and experiences9,60.  Coding of 
phenotype data will preserve the intended message as well as its integrity and biological 
significance; it will facilitate the wide-use application of a specific dataset across multiple 
domains.  The International Standards for Cytogenomic Arrays (ISCA) Consortium similarly 
recommends the use of standardized phenotype representation following a study demonstrating 
its effectiveness as compared to free-text descriptions on ISCA test requisition forms61.  Deep 
phenotyping methods and systematic annotation have clear clinical applications as well, 
particularly in the classification of genetic variation.  Therefore, the quality and quantity of 
useable data will significantly improve by harmonizing the terminologies of different phenotype 
databases, which will ultimately lead to better diagnostic assessments.   
1.2.4.1 Clinical Application 
Deep phenotyping can reveal variations in disease manifestation, diagnostic and 
prognostic time course, as well as therapeutic response9,11.  It can help validate human GWAS 
studies for disease associations and contribute to gene or pathway discoveries.   Deep 
phenotyping may also play a role in pharmacogenomics, dissection of copy number variation 
data, as well as candidate gene prioritization.  Deep phenotyping can identify patients with rare 
conditions or disease phenotypes for genetic analysis by systematically cataloging a phenotype 
spectrum.  Its data serve as a reference for the classification of variants of uncertain significance, 
likely clinically relevant genes, and otherwise benign, intragenic 
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microdeletions/microduplications that would be below a laboratory’s standard reporting 
threshold for size61.  The data can aid in predicting the pathogenicity of mutations and genotype-
phenotype correlations.  Closely-related phenotypes may be caused by mutations in different 
genes that either act directly and/or indirectly on the same pathway, or in the same gene.  For 
instance, mutations in the same gene can have diverse manifestations depending on the type and 
location of the mutation as well as epigenetic and environmental contrition.  Therefore, 
establishing nuanced genotype-phenotype profiles would help to predict the likelihood of 
developing a particular symptom or if the disease course will be mild or severe—i.e. a nonsense 
mutation occurring earlier in a gene may result in a more pronounced disease phenotype. 
Comprehensive phenotypic characterizations can also help differentiate between relatively non-
specific, e.g. “developmental delay” and “hypotonia”, or disease-associated features61. 
From a clinical perspective, delayed or inaccurate diagnoses can defer treatment and 
result in unnecessary medical interventions, which in turn contribute to a significant 
psychological burden for patients due to persistent testing or diagnostic odysseys.  In a study by 
the European Organization for Rare Diseases (EURODIS), 25% of patients with one of eight 
relatively common conditions, including Marfan syndrome, cystic fibrosis, and Fragile X 
syndrome, waited from 5 to 30 years for a diagnosis, which was initially wrong in 40% of the 
cases62. Overall, deep phenotyping in translational research can improve quality of care and 
medical management.  However, as the volume of genotype-phenotype information grows, it is 
increasingly necessary to develop a standardized and cohesive system to exploit the full potential 
of this research. 
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1.3 ONTOLOGIES 
In his initial Annual Report of the Registrar General in 1839, William Farr, who was the first 
medical statistician of the General Register Office of England and Wales, emphasized the need 
for a formal, standardized language that incorporated emerging medical developments.  Such a 
system would allow the classification of diseases and therefore, its causes, 9,63:  
“The advantages of a uniform statistical nomenclature, however 
imperfect, are so obvious, that it is surprising that no attention has 
been paid to its enforcement in Bills of Mortality. Each disease 
has, in many instances, been denoted by three or four terms, and 
each term has been applied to as many different diseases: vague, 
inconvenient names have been employed, or complications have 
been registered instead of primary diseases. The nomenclature is of 
as much importance in this department of enquiry as weights and 
measures in the physical sciences, and should be settled without 
delay.” (extracted from Franklin et al., 200863) 
 
Farr was describing an ontology or a structured, computational representation of a 
specific domain or field of knowledge4,64,65.  Ontologies are based upon a controlled, 
standardized vocabulary for describing heterogeneous entities or concepts with precise 
relationships and the semantic relationships between each2,4,13,64.  Entities are then used to 
compose coded phenotypic descriptions amenable to computation.  Ontologies provide a 
hierarchical and meaningful classification of the entities through which clinicians and 
researchers can describe, compare, and share their results within and outside the original domain.   
Ontologies have the potential to provide the organizational scaffold necessary for cross-domain 
integration and comparison of large volumes of information in databases. 
The entities contained within an ontology are granular, or in other words, reduced to its 
most basic components, such that phenotypic descriptions are highly specific and precise to the 
observed phenotype66.  Due to highly specialized structure and entities of ontologies, it is 
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difficult to harness the utility of multiple ontologies for cross-domain comparisons.  The 
semantic similarities between ontologies are not inherently equivalent and require extensive 
mapping of the semantic gap between entities14,15,67,68.  The incompatibility of the well-
established, yet fundamentally different, ontology design hinders the translation between 
ontologies and thereby its coded data.  
Currently, ontologies are developed for specific and narrow scopes, which obstruct large-
scale automated analysis across multiple species and domains.  Ontologies need to be 
computationally tractable and complementary in order to maximize the full benefit of animal 
models and deep phenotyping.  Research is ineffectual if its data cannot be analyzed or readily 
accessed and shared.  Ontologies are particularly advantageous for database functionality, 
because in contrast to free-text searches, ontology-based systems retrieve groups of related terms 
instead of only those matching the exact keyword used69.  Moreover, ontologies should be 
flexible, expandable, and dynamic to accommodate the mercurial nature of data, new 
discoveries, as well as input from the research community as it advances. 
The most successful ontology to date is the Gene Ontology (GO), which is utilized 
primarily by the molecular biology community (accessible at http://geneontology.org/).  The GO 
describes three main domains—molecular function, biological process, and cellular 
component—in over 11 million species-neutral annotations relating to gene products described 
in databases such as UniProt and Ensembl70.  The near ubiquitous use of GO makes it 
particularly valuable in the analysis of microarray results as it can determine if one or more 
biological theme is present within the dataset.  It has also demonstrated its efficacy in cross-
species data-mining71,72.   For the human genetics or clinical field, a unifying standard for 
phenotype annotation in ontologies has yet to be established.  
 20 
1.3.1 Heterogeneity of Current Ontologies 
Currently ontologies are independently developed to serve a single purpose for a particular 
domain, e.g. anatomy versus pathophysiology, mouse versus human, and research versus 
clinical, without complementary infrastructures or methods of design.  The data is highly 
complex and specific; the scope of information may not be readily translated both within- and 
cross-species.  For instance, vocabularies may be species-specific such that the anatomical 
structure present in one is absent or different in another, e.g. Drosophila wings and mouse tail.  
Moreover, while two terms may be logically different, the concepts or relationships it represents 
may be equivalent or identical, e.g. the anatomical similarity between human and whale 
forelimbs73.  Consequently, mapping concepts from one to another may not be straightforward or 
intuitive.   
Before mapping can be reliably conducted, the intrinsic incompatibility of ontologies 
must be harmonized.  The strength of ontologies is its tractability beyond one system or domain.  
There are three main issues that need attention.  Firstly, as discussed earlier, the heterogeneity of 
ontologies is a product of its scope, which in turn requires complex species- or domain-specific 
vocabularies. Secondly, incompleteness of terms within ontologies results in continual 
dependency on free-text descriptions, and lastly, the lack of standardization in the development 
of its representation format, e.g. contrasting pre- versus post-composed approaches, impedes 
accurate mapping of terms.   
In efforts to build a comprehensive suite of interoperable and orthogonal reference 
ontologies in the biomedical field across both species and scopes, the Open Biological and 
Biomedical Ontologies (OBO) Foundry, which is a collaborative, umbrella initiative that is part 
of the OBO, was developed (http://obofoundry.org/)70.  The OBO Foundry has created a 
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standard, but evolving set of formatting principles for ontology developers70.  Any ontology 
belonging to the OBO Foundry must adopt and maintain all sixteen of the Foundry Principles, 
which can be found online (available at 
http://www.obofoundry.org/wiki/index.php/Category:Principles).  Its mission has yet to be fully 
realized or implemented throughout the community due to the complexity of the data and the 
mapping required due to the diversity of ontologies used.  The ontologies belonging to the OBO 
Foundry are listed in Appendix A.1, Table 1.3.1.  
1.3.1.1 Free-Text Annotation 
In the clinical setting, annotation of a patient’s phenotype is still largely dependent on 
free-text or natural language descriptions61.  Although highly expressive and widely understood 
within a specific discipline, free-text descriptions are not amenable by computer programs, are 
vulnerable to ambiguity, and are impractical to maintain.  The pervasive clinical practice of free-
text annotations may be due to numerous factors, including practitioner habit, inadequate 
terminology contained in a given ontology, and/or desire to capture relevant information not 
within the realm of diagnostic codes, such as negative/normal findings or noting a specific 
family member with a genetic condition or exhibiting some of its features61.  Moreover, some 
phenotype descriptions e.g. the cat-cry in Cri-du-chat or the Greek warrior helmet appearance of 
individuals with Wolf-Hirschhorn syndrome (WHS), are difficult to express concisely or evoke 
the same message if written in coded terminology.  Nevertheless, it is difficult to utilize 
computational analysis on free-text descriptions that lack structure or formalized language.    
The International Classification of Diseases (ICD) is a prevalent clinical coding system 
used in health-administrative billing databases for describing human diseases and therapies by 
physicians.  ICD was created in 1893 and has since undergone numerous revisions that have 
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repeatedly expanded or restructured its contents.  CHD, in particular, is poorly represented in the 
ICD codes, with 29 and 73 individual CHD codes in the 9th and 10th revisions, respectively63.  
Many of the CHD codes included in the 9th revision (i.e. ICD-9) are bundled.  For instance, 
“tetralogy of Fallot” is attributed a single code (ICD-9 745.2), whereas clinical nomenclature 
may differentiate at least five variations: TOF with absent pulmonary valve, TOF with AVSD, 
DORV-TOF type, PA with VSD, and/or PA with VSD and major aortopulmonary collateral 
arteries (MAPCA)20.  Due to bundling, the ICD-9 technically classifies all patients with varying 
TOF-phenotypes with the same diagnosis.  A single code for a highly variable phenotype fails to 
distinguish less severe forms of CHD from those with more complex manifestations—such as 
PA with VSD compared to TOF alone—, which may have a significant impact on clinical 
management and prognosis.  It would subsequently limit research on the nuances of phenotype 
spectrums and genetic modifiers underlying variability in patients.  To compensate for such 
coding limitations, clinicians may revert to free-text annotations.  For instance, from 1997-1999, 
only 52% of diagnoses for CHD documented as free-text in medical records had a corresponding 
ICD-9 code in the Children’s Hospital of Wisconsin discharge database74.  
Moreover, free-text annotation is susceptible to numerous problems that impair its utility: 
spelling errors, regional/domain/individual variability, non-synonymous terminology used 
inappropriately, ambiguous abbreviations, as well as background noise or inclusion of irrelevant 
information.  These issues can lead to many false-negative and false-positive search query 
results.  For example, ambiguous abbreviations—such as “ASD” which could represent atrial 
septum defect or autism spectrum disorder—may not need clarification within a particular 
discipline, but to others could be interpreted incorrectly20.  Misattributing ASD to a 
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developmental disorder instead of a possibly severe CHD could have dangerous consequences 
for that patient.   
The Online Mendelian Inheritance in Man (OMIM) is a widely used online genetics 
resource developed by Professor Victor McKusick and Johns Hopkins University.  It is a text-
based database attempting to organize all the knowledge accumulated on genetic variation and 
clinical human disease in a single, searchable catalogue.  It focuses on Mendelian disorders and 
currently includes information of over 14,500 genes, of which over 3,100 (approximately 22%) 
are associated with a phenotype-causing mutation (extracted from http://omim.org).  While the 
information is continually updated and relatively comprehensive within its scope, its value 
suffers from its design.  OMIM is not formally structured and does not apply consistent 
terminology or logical definitions.  OMIM utilizes the Human Phenotype Ontology within its 
annotations but remains constrained by free-text curation without well-defined relationships 
between its entries, subsequently leading to inconsistencies and computational limitations, 
particularly in information retrieval.  
Examples of the inconsistencies of a text-based method and its effect on computational 
searches are illustrated below in Table 1.3.1.1.  As depicted in Table 1.3.1.1, a different number 
of records are returned with slight query variations for “micrognathia,” “anophthalmia,” and 
“microphthalmia.”  While varying queries for a feature may produce some redundancies, there 
are still apparent gaps.  Even subtle differences such as “absence of eyes” versus “absent eyes” 
yield half the number of results—4 versus 8, respectively—even though the queries are 
synonymous to the human user.  Altering the word order, e.g. “absent eyes” compared to “eyes 
absent”, similarly produces half the results—8 compared to 16, respectively.  Free-text based 
searches are further confounded by nuanced phenotypes as well as the dependency on the clinical 
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and diagnostic accuracy of the symptom.  Terms are often misused and variably defined 
depending on the user, and would subsequently be interpreted differently depending on the 
reader.  For instance, anophthalmia is indicated when the eye globe is absent with minimal 
residual tissue as detected by histology, although it is frequently applied in phenotype annotation 
based on visual observation alone58.  The user or reader may differentiate between histologically 
demonstrated anophthalmia as “primary” while others may not make that distinction.   
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Table 1.3.1.1 OMIM query results for “micrognathia”, “anophthalmia”, and “microphthalmia”  
OMIM Query Number of Results 
Variants of "micrognathia" 
 "micrognathia" 469 
"mandibular hypoplasia" 54 
"small mandible" 31 
"small jaw" 16 
"micrognathism" 4 
Variants of "anophthalmia" 
 "anophthalmia" 66 
"clinical anophthalmia" 44 
"no eye(s)" 26 
"severe microphthalmia" 23 
"anophthalmos" 12 
"primary anophthalmia" 12 
"eyes absent/absence" 16 
"absent/absence eye" 8 
"absence of eyes" 4 
Variants of "microphthalmia" 
"microphthalmia" 331 
"microphthalmos" 44 
"small eye(s)" 25 
"nanophthalmos" 12 
"clinical microphthalmia" 3 
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1.3.1.2 Pre- and Post-Composing Approaches 
There are two main approaches to constructing ontology and how to establish the 
semantic relationships within it: pre- and post-composing1.  The main difference between the 
strategies is that the annotator composes the phenotype descriptions at the time of the annotation 
in the latter whereas the former, pre-composition, requires the annotator to choose the 
appropriate phenotype description from a predetermined list of terms.  There are different 
benefits and limitations to each strategy.   
Post-composed formats include the popular bipartite Entity + Quality (or E+Q) method, 
which utilizes various ontologies to build a single phenotype description.  In the E+Q method, a 
bearer entity, e.g. from an anatomy or process ontology such as Adult Mouse Anatomy (MA) or 
Foundational Model Anatomy (FMA), is described by a quality1,67,75,76.  Quality terms are 
typically annotated with the Phenotype and Trait Ontology (PATO).  For instance, to describe 
“microphthalmia” with the E+Q method, E = “eye” (MA:0000261) + Q = “small” 
(PATO:0000587).   The phenotype “microphthalmia” has been reduced to its component parts: 
“small” and “eye”.   The E+Q approach allows for the implicit representation of traits (e.g. “eye 
+ size”) in its phenotype descriptions (e.g. “eye + small”)1.  Modifier terms (M) and additional 
entity terms for relational qualities (E2) may increase expressivity of a phenotype description1.  
Therefore, “abnormal kidney shape” would be: E = “kidney” (MA:0000368) + Q = 
“morphology” (PATO:0000051) + M = “abnormal” (PATO:0000460).  Similarly, “overriding 
aorta” would be: E1 = “aorta” (FMA:3734) + Q = “overlap with” (PATO:0001590) + E2 = 
“membranous interventricular septum” (FMA:7135).  E+Q syntax is advantageous as it allows 
better flexibility and integration of multiple ontologies for the creation of a single entity.  
However, the E+Q method is limited in describing complex phenotypes, such as “jaundice”, for 
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which multiple E+Q statements are required to express the phenotype by its essential 
components77.  Furthermore, the post-composing approach relies more heavily on the curator 
accuracy and expertise in the phenotype or ontologies.  
The most widely used ontologies, such as the GO as well as the Human Phenotype (HPO) 
and Mammalian Phenotype (MP) ontologies, are pre-composed and represented in the form of 
directed cyclic graphs (DAG)11,78,79.  DAGs are structured in a series of interconnected nodes (or 
terms) with each link or edge between a set of nodes denoting a semantic relationship (e.g. “is_a” 
or “part_of”)2,13,77,80.  Individual nodes, for instance “atrial septal defect”, represent a specific 
component or subclass of a more general parent term, i.e. “organ abnormality” as illustrated in 
Figure 1.3.1.2.a.  In other words, an “atrial septal defect is_an organ abnormality.”  Moreover, 
every entity annotated to a particular node is implicitly annotated to all ancestors of that term, 
which is called the true-path rule2,81.  DAG terms may have multiple parents, which would 
reflect multiple semantic relationships, and different terms may share a same parent term.  The 
farther a node is from the parent term, the more specificity it represents. “Atrial septal defect” 
represents a more specific type of “organ abnormality” than “cardiac malformation.”  The 
implicit, hierarchical structure of DAGs is advantageous for computation as algorithms can 
exploit the semantic relationships between nodes to retrieve related data annotated to the 
keyword as well.  Pre-composed ontologies are also adept at describing complex phenotypes 
concisely.  For instance “microphthalmia”, “abnormal kidney shape”, and “overriding aorta” in 
MP terms would be MP:0001297, MP:0001297, and MP:0000273, respectively. 
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Figure 1.3.1.2.a. DAG representation of HPO term “atrial septa defect” (adapted from Kohler et al.13) 
(a) Human Phenotype Ontology 
 
The Human Phenotype Ontology (HPO) aims to create a standardized vocabulary for 
abnormal phenotypes, including onset, clinical course, mode of inheritance, and other observable 
manifestations associated with human disease2,11,82.  It was initially constructed in 2007 using 
OMIM datasets with the mission to provide a basis for computational analysis, and subsequently 
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database cataloging, of the human disease phenotypes82.  The HPO currently has over 50,000 
annotations to specific diseases within OMIM and more than 10,000 distinct HPO terms of 
phenotypic abnormality, each labeled with a unique identifier code (HP:7-digit number) and 
describe a phenotype associated with human disease11.  In order to provide a more 
comprehensive and accurate representation of reported phenotypes, HPO is continually 
redefining and expanding its vocabulary.  Recently, the HPO is collaborating with the OBO 
Foundry to further develop its compatibility in biomedical databases and with other commonly 
used ontologies, such as PATO, GO, and FMA.  Complex, pre-composed HPO terms will be 
additionally annotated with logical definitions, which translate HPO terms into E+Q syntax.   
Robinson and Mundlos2 demonstrated the applicability of the HPO for statistical analysis 
and differential diagnoses in a free, online program called the Phenomizer, which was developed 
by the HPO group (http://compbio.charite.de/phenomizer/).  The Phenomizer allows users to 
enter clinical features of a patient, select the appropriate HPO terms, designate suspected mode 
of inheritance, and differentiate mandatory versus observed findings83.  The program then 
calculates the semantic similarity of the entered features with diseases directly or indirectly 
annotated to the chosen HPO terms and provides a list of differential diagnoses according to 
significant p-values83.  The program provides links to available OMIM entries and PDF exports 
of search results.  This program would aid in the query of phenotype databases.   
(b) Mammalian Phenotype Ontology 
The Mammalian Phenotype (MP) Ontology is one of the most comprehensive pre-
composed ontologies describing aspects of abnormal anatomy, phenotypes, and processes 
associated with disease in mammals, notably mouse and rat79.  The MP Ontology, developed by 
the Jackson Laboratory (JAX), adheres to the OBO format and OBO Foundry Principles, but is 
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not currently a member of the OBO Foundry initiative77.  Currently, there are 9,804 MP terms 
available with 51,438 mouse genotypes annotated to a total of 267,297 MP in the JAX Mouse 
Genome Database (MGD, extracted from 
http://www.informatics.jax.org/mgihome/homepages/stats/all_stats.shtml and accessible at 
http://www.informatics.jax.org/).  A statistical summary of relevant MGD data and annotations 
is in Appendix A.1, Table 1.3.1.2.   
Each MP-genotype annotation is supported by at least one reference; an example of 
annotated information for “overriding aortic valve” can be seen in Appendix B.1, Figure 
1.3.1.2.b.  The MP Ontology utilizes a DAG format with its semantic relationships structured 
similarly to the HPO.  Top-level (general/parent) terms include physiological systems, behavior, 
developmental phenotypes, and survival/aging.  Users can search or browse for any term within a 
path of nodes and retrieve all hierarchical children and parent phenotypes annotated to it 
(accessible at http://www.informatics.jax.org/searches/MP_form.shtml).  As illustrated in 
Appendix B.1, Figure 1.3.1.2.c for “overriding aortic valve”, every MP term is detailed with 
known synonyms, abbreviations or acronyms, definition, number of different paths (or edges) to 
term, as well as a unique MP ID (MP:6-digit number) and alternate Fyler Code ID number.  The 
Fyler Code may be downloaded at 
http://www.ipccc.net/Download%20the%20IPCCC/DownloadM.htm.  This is especially useful 
for CHD because the Fyler Code, which was developed by the Boston Children’s Heart 
Foundation in Boston Children’s Hospital, provides a clinical classification of CHD that can be 
cross-referenced by the International Pediatric and Congenital Cardiac Codes (IPCCC, 
http://www.ipccc.net).   
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1.3.2 Ontology Mapping and Harmonization 
There is a need to create mappings among ontologies in order to facilitate integration of data 
across multiple domains and benefit translational research.  Harmonization will improve 
ontology compatibility. Even within the same domain, there may be multiple ontologies 
represented—each providing a different scope or coverage of information, which may or may not 
overlap.  Ontology mapping strives to cross-reference or align entities across ontologies and 
establish semantic relationships between them without redundancy or translation 
inaccuracies68,78,84.   Accurate mapping would allow phenotypic annotations in model organisms 
to be related to the genetic pathophysiology, which can be directly linked to the human genome 
as well as other annotated sources.  Comparison of phenotypes to one another as well as to other 
domains of research depends on the quality and coherence of the ontologies and databases. 
Mapping contrasts from merging ontologies, which produces a single ontology, as it 
maintains the innate characteristics of each ontological concept in the final comprehensive 
system10,50,68.  Mapping two ontologies can be accomplished pairwise whereby an alignment is 
created directly between every entity or, alternatively, they can be mapped indirectly through 
intermediate reference ontology10,12,84,85.  Equivalence mapping between pre- and post-composed 
ontologies are feasible, although require careful curation for inconsistencies and lost semantic 
relationships are common due to the inherent complexities of pre-composed terms76,86.  For 
instance, MP term “situs inversus” (MP:0002766) can be broken down into its constituent 
components, or in other words, translated into an E+Q description: E = “visceral organ system” 
(MA:0000019) + Q = “inverted” (PATO:0000625).  Decomposing pre-composed ontologies into 
an E+Q syntax and mapping the resulting translations into logical definitions would exploit the 
strengths of both strategies.  Namely, it would utilize the user-friendly and concise concepts of 
 32 
pre-composed ontologies as well as the computer-amenable and customizable structure of post-
composing.  Nevertheless, these differences in ontology architecture do not fully support 
automated mapping and would require extensive validation.  
A standardized format for annotations would not only minimize experimental bias and 
curator variation/error, but also enable algorithms to conduct direct or cross-species functional 
correlations.  The OBO Foundry initiative developed guidelines to aid in the standardization as 
discussed in Section 1.3.1.  Each OBO Foundry ontology adopts a common graph-theoretic 
structure, which is similar to the DAG model70.  Relational expressions between terms will be 
provided by the OBO Common Anatomy Reference Ontology (CARO) in an “is_a” hierarchy to 
ensure logical coherence, improve consistency, and prevent common errors70,87.  Complex 
phenotype descriptions can then be custom composed using terms taken from any of the OBO 
Foundry ontologies with the CARO as the coherent glue between entities69,84,87.  This project 
utilizes alignment through a reference ontology, which serves as the common template or 
framework.  A standardized representation format will facilitate harmonization between the 
ontologies utilized.  Post-composition avoids bottlenecks that can result from using the pre-
composed strategies, in which each new term must be approved for inclusion before it can be 
annotated.  Zhang et al, demonstrated the superior efficiency and feasibility of indirect mapping 
through reference ontologies when compared to pairwise alignment85.   
Attempts to bridge cross-species ontologies—typically through pairwise alignment 
strategies—have had varying success.  In part, this is due to challenges in comparisons between 
the phenotypes and anatomies of animal models and its human counterpart.   For example, both 
mouse and human can develop TOF, but TOF cannot occur in zebrafish due its heart anatomical 
structure.   In other instances, it may not be a matter of a concept existing in one species and not 
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the other, but rather that orthologous organs between species have different component parts.  
For instance, the number of lobes of right lung in mice and humans are 5 and 3, respectively.  
Unequivocal correspondences such as these make it difficult to conduct mapping.    
A multi-species ontology called UBERON attempts to bridge the gap between species-
specific vertebrate anatomies by generalizing the anatomical structures in each respective 
ontology and relating these terms to UBERON superclass terms88.  It provides a reference 
framework on which to bridge anatomical structures between species.  For example, linking the 
mouse cochlea (MA: cochlea) with the human pinna (FMA: pinna) in the respective ontologies is 
the UBERON superclass “ear”.   Subsuming the superclass is the common UBERON node 
“internal ear” through which mouse and human are linked. 
Another cross-species mapping tool is PhenomicDB, which integrates multi-species 
genotype-phenotype associations from a wide-range of public model organism databases—
including yeast, zebrafish, worm, fly, plant, and mouse—as well as human disease phenotypes 
from OMIM (accessible at www.phenomicdb.de/ )89,90.  Algorithms group genes with 
overlapping phenotypes into phenoclusters to promote discoveries in phenogenomics.  It was 
demonstrated in an analysis of cross-species clustering within PhenomicDB that more than 90% 
of retrieved phenoclusters contained genes from a single species and that the genes tended to 
aggregate into species-specific clusters as well89.   
In summary, mapping tools aim to bridge the gap between ontologies so that its entities 
and semantic relationships are not corrupted or lost during translation.  As there is no singular 
reference ontology or standardized template to serve as a relational framework and promote 
intrinsic harmonization, a substantial degree of manual curation is still required to confirm these 
mappings for accurate translation. 
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1.4 BIOMEDICAL DATABASES 
Biomedical databases allow the collaborative and biologically meaningful interpretation of 
disease-related genetic and phenotypic information by both human-user and computer query; 
databases allow the analysis of disease variability, relationships between model organisms and 
human disease as well as the pathways of gene mutations to phenotypes73,80,91.  As our 
understanding of pathophysiology, genes, and disease manifestations increases, new methods 
need to be developed to acquire, archive, and analyze the data.  Biomedical databases have 
assumed the brunt of this load but much is still in need of development/improvement.   
The utility of databases is limited by the quality and accessibility of the data being 
submitted.  If the data quality is unorganized or laden with irrelevant and/or erroneous 
information, then it is useless beyond the depositing researcher/clinician and that specific 
sample/patient.  Moreover, if neither computer nor human user can reliably and fully access the 
data without significant loss of meaning, then again, the data is ineffectual.  In addition, the 
ultimate goal of translational and biomedical research is not limited within the scope of a 
singular person, disease, or gene but to all of public health.  Therefore, the data must be 
searchable as well as accessible across multiple databases and domains.  
 Currently, the wealth of scientific and clinical data in the community is dispersed in 
multiple databases across the world.  Nearly every group in every domain has its own repository 
for data and each type is represented according to the specific purposes of the center.  To realize 
the full potential of these databases in understanding human disease, the data must be openly and 
systematically accessible in an interconnected, interoperable network.  It would be of limited 
benefit for the information to be only accessible to those who know where to look or if one had 
to search multiple databases for the same query.  To achieve data integration, it will initially 
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require active collaboration between databases, such that each secondary or tertiary database 
gathers, collects, and transfers data to a centralized database, which, in turn, serves as the 
primary hub and host the user-interface.  
To facilitate interoperability between databases, there must be a standard language and 
format imposed.  Adoption of compatible phenotype and disease ontologies permits integration 
of vast amounts of knowledge between resources.  Ideally, this structural compatibility will 
promote automatic mining of data and therefore further research and clinical applicability.  This 
is particularly true for rare or uncommon diseases, such as emerging microdeletion or 
microduplication syndromes, for which statistical frequency or phenotype information is scarce 
and access to a global pool of disease data can increase sample size61.  
1.4.1 Potential Power of Databases 
Publically accessible repositories of genotype-phenotype information have implications for case-
based reasoning, variant prioritization, medical management, and differential diagnosis support.  
Formal ontologies could allow computational mining of relevant cases at an international level 
from findings reported in literature, basic science, and patient databases.  As genotype-phenotype 
correlations observed in clinic are more affected by pleiotropic confounders and variability than 
in the laboratory, it can be challenging for a clinician to identify a pattern suggestive of a 
particular condition.  However, while a patient’s individual features may not be traditionally 
associated with a disease, amongst the population of those affected, it may be observed with 
moderate frequency.  A mineable database for such information would allow users to identify 
similar cases, calculate clinical similarity between phenotypes, and interpret the most likely 
differentials.   
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An integrated database network utilizing ontologies would be able to predict multiple 
differentials and genetic profiles for a given phenotypic spectrum.  Ontology-based software 
tools for differential diagnoses, such as The Phenomizer, can help support diagnostic 
interpretation with evidence from a variety of resources.  For rare or orphan genetic conditions, 
an electronic network of such clinical findings could have tremendous input in differential 
diagnoses and treatment plans for both the individual and the family.  Features observed in 
similar cases may direct therapies or screening of previously unappreciated organ systems.  
Time-sensitive decisions, such as family planning options, and counseling can further benefit.   
1.4.2 Database Integration 
The wealth of knowledge accumulating in databases needs to be shared.  Sharing should be 
ubiquitous, dynamic, and automated.  The most effective method of accomplishing widespread 
data application and analysis across multiple domains and species can be facilitated by 
computational methods.  While the human mind may be more flexible than a computer 
algorithm, the latter more readily delineates subtle patterns among mass volumes of data.  
Databases are currently autonomous repositories that may provide links to other resources, but 
do not actively integrate the outsourced data with its own.  Ideally, to best exploit ongoing 
research, the community needs a centralized, integrated database that has the ability to query 
multiple data repositories from a single interface73,91.  The peripheral secondary and tertiary 
databases would maintain its independence and internal capabilities, but would regularly and 
methodically upload its data to the main primary server.  This federated network model would 
drastically improve efficiency and scientific discovery.  However, for disparate databases to 
successfully integrate or communicate, they must speak the same language.  
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The main translation obstacle for multi-database integration is the data itself.  Database 
systems cannot reliably recognize free-text descriptions that are often used in deep phenotyping. 
While free-text descriptions may never be replaced, it can be augmented by a standardized, 
logically formatted language that is decipherable by multiple databases.   Ontologies are the ideal 
structures to bridge the gap between phenotype observation and database utilization.  As 
discussed in Section 1.3, there must first be harmony between different ontologies to facilitate 
database interoperability and therefore, integration.   
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2.0  MODELING THE GENETIC BASIS FOR HUMAN CHD IN MICE  
2.1 NHLBI BENCH TO BASSINET PROGRAM 
In September 2009, NHLBI launched the B2B program, which is a novel translational research 
program in pediatric cardiovascular disease.  The B2B program is a multi-centered collaborative 
effort designed to accelerate the translation of basic research findings into clinical studies across 
two interacting consortia: CvDC and PCGC; the B2B also coordinates with the NHLBI-funded 
PHN established in 200121,49.   The program brings together enormous quantities of data 
generated by state-of-the-art, coordinated research at both bench- and bassinet-sides through 
active communication and cooperation.  The consortia are organized in such a way as to 
maximize the integration from discovery (CvDC) to early, tier 1 (T1) human clinical research 
(PCGC) to patient application (PHN).  At the time this dissertation was written, New England 
Research Institutes (NERI) acted as the data- (DCC) and administrative-coordinating center 
(ACC) within the PHN and between the CvDC and the PCGC, respectively.  The B2B network 
with the participating centers and overarching design is illustrated in Figure 2.1 from Lauer and 
Skarlatos49.   
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Figure 2.1. The Bench to Bassinet program network. Figure from Lauer and Skarlatos49 
 
The list of centers and project titles of the B2B consortia, e.g. CvDC and PCGC, as well 
as the PHN, can be found in Appendix A.3, Tables 2.1.a and 2.1.b.  Each consortium or network 
and its participating centers have its own research goals under the primary mission of improving 
the understanding of CHD etiology for better patient care and ultimately prevention21.  The 
CvDC is a part of the discovery phase and aims to build a more precise model of the complex 
regulatory networks of CHD and heart development.  The CvDC will implement various 
genome-wide approaches and high-throughput techniques on complementary animal models 
such as mouse, chick, and zebrafish21.  The PCGC applies CvDC discoveries in clinically-
relevant genomic studies on pediatric participants; it utilizes recent advances in large-scale 
genetic techniques to facilitate the discovery of CHD genes and to evaluate potential genotype-
phenotype correlations on short- and long-term outcomes21,49.   The CvDC and PCGC will also 
collaborate with the PHN, which is a clinical network of academic institutions in the United 
States and Canada that are conducting research to improve therapies for children with both 
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congenital and acquired heart disease21.   Recruiting participants from various centers under a 
common protocol as well as through the PHN provides access to a larger subset of the CHD 
population. 
2.2 UNIVERSITY OF PITTSBURGH ENU MUTAGENESIS SCREEN 
The University of Pittsburgh participates in the CvDC of the B2B program under the direction of 
Dr. Cecelia Lo.  Her project title is “Modeling the Genetic Basis for Human Congenital Heart 
Disease in Mice” and utilizes the N-ethyl-N-nitrosurea (ENU) method to biochemically generate 
mutant mouse models of a wide-range of CHD.  During the mutagenesis screen, curated data 
may be publically accessed through two portals: MGD and B2B Mouse ENU Mutation Database 
(accessible at http://www.benchtobassinet.net/CvDCMouseMutations.asp). 
2.2.1 ENU Screen Methodologies 
Figure 2.2.1 below illustrates the overall mutagenesis screen workflow (solid lines) from the 
generation of generation (G)0 mutant CHD mice to curation of a finalized mutant line that is 
accessible from three databases (yellow): in-house ENU, MGD, and B2B.  Green boxes indicate 
pages on the ENU database that represent selected data, which has been uploaded (dotted lines) 
by its respective group.  The schema in Figure 2.2.1 depicts an outline of the methodologies 
utilized for CHD diagnosis and identification of candidate gene and pathogenic mutations as well 
as the considerations (blue) made by the curator during mutant line characterization.  Red circles 
signify points at which data is translated either between scientific observations, free-text 
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annotation, and/or various coding systems/ontologies.  More detailed methodology is described 
in the following sections.  
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Figure 2.2.1. Schema of ENU screen workflow 
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2.2.1.1 ENU Mutagenesis and Generation of Mice 
N-ethyl-N-nitrosurea (ENU) was used to biochemically induce multiple, single 
nucleotide polymorphisms (SNP) in C57BL6/J mice.  G0 males were injected with fractionated 
ENU doses (80 mg/kg of body weight, three times at weekly intervals).  After 10 weeks, which 
allowed time for fertility recovery, the mutagenized males were mated to C57BL6/J female mice.  
The resulting G1 males were then mated to new C57BL/6J females to generate G2 females, 
which were then backcrossed to the respective G1 father.  Inbred G3 litters were prenatally 
screened for CHD by ultrasound imaging and Doppler echocardiography.   
2.2.1.2 Imaging Techniques and Diagnoses  
All images and videos are uploaded onto the University of Pittsburgh ENU database as 
well as the shared laboratory server (ENU database accessible with log in at 
http://apps.devbio.pitt.edu/LabENU/Account/LogOn?).  A multi-tiered strategy utilizing 
numerous modalities as primary and secondary phenotyping assays identifies mutant CHD 
samples.  Select images and videos from relevant samples are chosen for inclusion on the mutant 
line page with a subset of media promoted for MGD upload.  Data are also regularly uploaded to 
the B2B portal.   
(a) Ultrasound imaging and Doppler echocardiography 
Acuson Sequoia C256 ultrasound system with a 15 MHz L8 linear phased array 
transducer was used for first-tier screening of CHD92.  Fetuses were scanned from embryonic 
day (E)13.5 to E15.5, which is the ideal gestation period in order to minimize false-positives 
reflecting developmental delay due to incomplete septation of the ventricular chamber and 
outflow tract (OFT) until E13.5 to E14.592.  Second-tier of analysis of litters with abnormal 
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findings detected by Acuson was performed by Vevo2100 UBM with a 40 MHz transducer92.  
Combined with color flow and spectral Doppler imaging, which visualizes blood velocity and 
circulation, potential mutants can be quickly identified for subsequent imaging analysis by 
micro-CT or micro-MRI.  Frequently observed was comorbidity with possible CHD and 
pericardial effusion (24.6%), hydrops (24.6%), or growth restrictions (6.5%) (data extrapolated 
from ENU database unpublished summary report on 25 April 2014)92. 
(b) micro-CT and micro-MRI  
Micro-CT and micro-MRI were primary assays implemented as a secondary imaging 
modality after ultrasound and echocardiography.  The former technique uses ionizing radiation 
for 3D visualization of the whole mouse anatomy.  In comparison, micro-MRI converts changes 
in the magnetic field of atoms, primarily hydrogen, into high-resolution 2D or 3D images of a 
target tissue. Each method has different advantages and disadvantages, including efficiency, 
resolution, and image size.  For instance, micro-MRI is limited to post-mortem samples due to 
sensitivity to movement during the procedure but can interrogate more samples simultaneously 
than micro-CT92.  Findings are annotated according to a pre-composed set of microCT defect 
codes and free-text notes.  The current set of microCT defect codes annotated in the ENU 
database can be downloaded from the ENU database (accessible with log in at 
http://apps.devbio.pitt.edu/LabENU/Report).  Consensus of at least two experts, e.g. pediatric 
cardiologists and/or pathologist, is required for each sample.  Fetuses or pups identified to have a 
suspected CHD by micro-CT or micro-MRI are then nominated for further phenotype analysis 
by secondary assays, including necropsy and histopathology evaluation.   
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(c) Necropsy 
Stillborn pups, mice that died within a day of birth, or mice that were nominated for 
further analysis are retrieved and fixed in 10% buffered formalin prior to necropsy.  Necropsy 
examines the overall heart orientation (e.g. dextrocardia) as well as its great vessels (e.g. parallel 
OFT or persistent truncus arteriosus, PTA) and possible aortic arch arteries (e.g. right or 
interrupted aortic arch).  Importantly, necropsy can also observe non-cardiac anomalies, 
including craniofacial (e.g. anophthalmia or cleft lip/palate), laterality (e.g. situs solitus/inversus, 
dextrogastria or pulmonary isomerism), body wall (e.g. gastroschisis), skeletal (e.g. absent or 
unfused sternal vertebra), limb (e.g. polydactyly or abnormally attached hindlimbs), and other 
organ (e.g. kidney agenesis, hydronephrosis, or hypoplastic thymus) abnormalities.  The trachea 
of CHD pups exhibiting laterality defects were harvested and scraped for immunostaining.  
Videomicroscopy using a Leica DMIRE2 inverted microscope and DIC optics is performed to 
characterize airway cilia as normal, dyskinetic, hyperkinetic, motile, immotile, and/or slow51.  
Necropsy results may implicate CHD, but histopathology is necessary to confirm a CHD 
diagnosis.  All defects and findings are thoroughly annotated as free-text notes and as a subset of 
pre-composed necropsy defect codes.  The current set of necropsy defect codes annotated in the 
ENU database can be downloaded from the ENU database (accessible with log in at 
http://apps.devbio.pitt.edu/LabENU/Report). 
(d) Histopathology with EFIC 
Histopathology is the gold standard for the precise diagnosis and confirmation of CHD.  
Pioneered by Weninger et al., episcopic fluorescence image capture (EFIC) detects minute 
intracardiac structures and allows rapid 2D and 3D reconstructions of the heart by analyzing 
serial cross-sections of the heart at different angles93.  The University of Pittsburgh mutagenesis 
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screen utilized a Leica SM2500 sledge microtome, which was customized with a MZFLIII 
stereomicroscope equipped for fluorescence imaging92.  Findings are annotated according to a 
pre-composed set of EFIC defect codes and captured with a summary sheet ascribing all relevant 
diagnoses for that sample.  The current set of EFIC defect codes annotated in the ENU database 
is listed in Appendix B.4, Table 2.2.1.2.  A panel of at least one pediatric cardiologist and one 
pathologist review all EFIC findings in order approve the final diagnosis.   
2.2.1.3 Genetic Analysis  
The genotype of each mutant CHD line is characterized by whole exome sequencing 
(WES, performed by Beijing Genomics Institute, BGI) of a single, representative mutant sample.  
BGI returns a mapped sequencing file of all the identified variants, which are then annotated 
using ANNOVAR (available at http://www.openbioinformatics.org/annovar/) and coded as 
nonsynonymous, synonymous, or splicing variants.  Homozygous calls are then filtered against 
dbSNP128 and in-house mouse exome databases (available from the GNomEx CvDC Datahub at 
http://sb2b.hci.utah.edu/gnomex/gnomexGuestFLex.jsp?topicNumber=67).  Conservation of a 
nucleotide in an altered gene is analyzed using the University of California, Santa Cruz (UCSC) 
Genome Browser (accessible at http://genome.ucsc.edu/).  Highly conserved nucleotides serve as 
possible indicators for biological importance and thus, may be disease-causing.  The remaining 
homozygous calls are prioritized and validated by further genotypic and phenotypic analysis.  
For example, CHD phenotypes should co-segregate with the candidate gene and respective 
pathogenic mutation.  In instances of more than one mutation on the same chromosome being 
linked to a phenotype, the pathogenic mutation was identified by segregation analysis of 
additional mutants and/or phenotype comparison to existing knockout or mutant alleles reported 
in literature.  
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 Purified polymerase chain reaction (PCR) products of mutant samples are genotyped by 
Sanger DNA sequencing at Genewiz (http://www.genewiz.com/index.aspx) and 
electropherogram analysis using 4peaks software (available at 
http://nucleobytes.com/index.php/4peaks).  Primers for PCR and Sanger DNA sequencing are 
custom designed in-house with Primer3 online program (accessible at 
http://biotools.umassmed.edu/bioapps/primer3_www.cgi) and synthesized by Integrated DNA 
technologies (http://www.idtdna.com/).  Mutant G3 pups as well as G1 and G2 adults were 
genotyped.  Heterozygous adults were set up for breeding to produce either heterozygous G2 
females or homozygous G3 progeny.  Tracking mutant G3 genotypes with confirmed CHD 
phenotypes supported validation of candidate genes.  Extensive genotyping, e.g. checking for 
multiple mutations in a line, of G3 pups can also be performed to nominate candidate genes 
during early stages of gene prioritization analysis or if the phenotype no longer segregates with 
the assumed genotype.  
2.2.1.4 Cryopreservation  
The sperm of the original mutagenized G1 male was cryopreserved.  Cryopreservation is 
both a cost- and time-effective method of archiving a particular genetic profile with limited 
contamination and information loss, or paying for mouse husbandry maintenance.  All curated 
B2B line pages on MGD contain links to the Jackson Laboratory International Mutant Strain 
Resource (IMSR), which serves as a repository for all recovered mouse mutants (accessible at 
http://www.findmice.org/).  Interested researchers may order mice with the same genetic 
background as the original ENU G1 male.  
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2.2.2 Curation of Data 
Curation is the analysis, organization, and collection of immense data in various forms of genetic 
and phenotypic evidence.  In the context of the mutagenesis screen, curation transforms selected 
and validated data into a representative summary or mutant line for a specific set of reliable and 
reproducible findings.  The diagnosed phenotypic spectrum is maintained, i.e. inherited, across 
multiple G3 fetuses of the same mutant line and therefore, the same genetic defect.  Each mutant 
line was curated in a standardized format with high quality control that demonstrates cross-
modality consistency.  Mutant lines are thoroughly reviewed by a panel of experts—including 
pediatric cardiologists, pathologists, clinicians, as well as experienced scientists—before direct 
submission and upload to MGD.  Ultimately, this curation process produced a comprehensive 
catalogue of ongoing CHD genetics research in mice that is readily accessible and interpretable 
through MGD by researchers, health care professionals, and aligned computer databases or 
search algorithms.  
 Every sample in a curated mutant line was reviewed and its phenotypic data evaluated for 
consistency within itself as well as compared to other mutants in the line.  After all the available 
samples have been examined and annotated as both free-text and coded annotations for each 
respective modality, a summative diagnosis was formulated.  The summative diagnosis 
represents the comprehensive phenotypic spectrum associated with that line and is based on the 
reliable phenotypic pattern (e.g. at least two mutants or at least two closely-related CHD 
phenotypes) observed across all samples.  The summative diagnosis is initially written as a free-
text description of the cardiovascular and non-cardiovascular phenotypes, then translated into 
corresponding Fyler Codes.  The curator inputs the appropriate Fyler Codes on the mutant line 
page. 
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 Mutant lines were additionally curated with the Fyler Code to enable users from the 
PCGC and PHN to readily query data on either the B2B portal or MGD.  Fyler Codes are 
included as secondary annotations on MGD as the scope of the MP Ontology does not emphasize 
CHD.  The Fyler Code helps align the MP Ontology to current CHD standards and knowledge79.   
Once a mutant line page had been thoroughly edited and enough evidence gathered to 
confidently associate a pathogenic mutation with a specific phenotype spectrum, it undergoes a 
final review by a panel of experts in the various diagnoses modalities.   
During this review, the summative diagnosis is confirmed and the mutant line finalized.  
The images and videos that best demonstrate the summative diagnosis are confirmed for MGD 
upload.  Captions are added or edited to selected images according to a template for consistency 
as well as to ensure that each image is self-explanatory and autonomous.  For instance, all EFIC 
images are phrased similarly, e.g. “Serial 2D EFIC image stack in the coronal plane of…[mutant 
ID]…reveals [CHD diagnosis]”.  Images are then organized by sample and for each sample, the 
CHD images are ordered first, followed by images depicting the noncardiovascular phenotype.  
Image order in the ENU database is reflected in the MGD version.   
Lastly, the line is selected as “MGD ready” and the MGD curator is notified.   Within the 
MGD system, mutant lines are re-identified as “b2b[line number]clo”.  If the contributing gene 
and mutation had been thoroughly validated, then it may be elected for publication on MGD.  
The corresponding line would be annotated accordingly as “geneb2b[line number]clo”.  Genetic 
information may also be added at any point after it had been uploaded MGD.  If any changes, 
including the addition or removal of data, are made to a published line, the “Update” field is 
selected within the ENU database and the MGD liaison is informed directly with detailed notes 
of the changes. 
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2.2.2.1 Public Access to Data 
One of the chief goals of the B2B program is to promote dynamic communication of knowledge 
in order to facilitate collaborative discoveries in translational research.  It achieves its goal by 
encouraging transparency and public access to its data.  Interested and invested individuals—
including scientists, clinical researchers, physicians, as well as the informed public—can readily 
explore recent findings through two main portals: B2B and MGD.  Discoveries included on these 
databases may or may not be published yet in scientific journals.   
2.2.3 Synopsis of ENU Screen 
N-ethyl-N-nitrosurea (ENU) was used to biochemically induce multiple, single nucleotide 
polymorphisms (SNP) in C57BL6/J male G0 mice.  Each mutagenized mouse is then bred to 
generate a mouse model or mutant line of CHD.  Resultant mutant pups or samples are screened 
for CHD as well as non-cardiac anomalies using a wide-repertoire of techniques: ultrasound 
imaging, Doppler echocardiography, micro-computed tomography (micro-CT) and micro–
magnetic resonance imaging (micro-MRI), necropsy, EFIC, as well as various 
immunohistochemistry methods.  WES as well as candidate gene validation by PCR and Sanger 
sequencing analysis were used to identify disease-causing homozygous mutations in G3 mutant 
lines.  Further validation requires maintained genotype-phenotype correlations across multiple 
mutants of a given line. 
Data for over 200 mutant lines are curated onto the MGD and B2B databases for public 
assess.  Accomplishments of the mutagenesis screen as of 25 April 2014 are summarized below 
in Table 2.2.3 and include: 82,547 fetal mice from over 3,00 mutant lines screened by 
ultrasound; 7,996 homozygous/heterozygous mutations in 4,809 genes recovered by WES; 235 
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distinct mutant lines cryopreserved; 184 mutant lines curated and represented on MGD with 62 
associated with a human disease (33.7%); and 201 lines analyzed by WES with 107 pathogenic 
mutations validated (53.2% recovery rate) in 68 unique genes. 
 
Table 2.2.3. Summary of ENU mutagenesis screen statistics 
Statistics as of 25 April 2014 Total Number 
Fetal Mice Screened by Ultrasound 82,547 
Mutant Lines Screened for CHD 3,091 
Mutant Lines Cryopreserved 235 
Mutant Lines Curated on MGD 184 
Mutant Lines with Whole-Exome Analysis 201 
Validated Pathogenic Mutations  107 
Unique Genes with Pathogenic Mutations 68B,C 
Human Disease Models with Validated Gene 62 
Mutations Recovered 7,996A,B 
Genes with Mutations Recovered 4,809B 
    
Notes: 
 AIncludes both homozygous and heterozygous mutations 
BRedundant findings not included 
CGenes with multiple disease-causing alleles include those related to laterality 
 
Pathogenic mutations have been found in genes involved in CHD pathways, such as 
ciliopathy (e.g. Tmem67 and Dnahc5), vesicular (e.g. Lrp1) and cellular trafficking (e.g. Megf8 
and Kif7), as well as extracellular matrix (e.g. Adamts6 and Mmp21) (from unpublished 
manuscript)94–99.  Human diseases have been associated with many mutant lines either based on 
genetic or phenotypic comparisons.  Selected human diseases include Primary Ciliary Dyskinesia 
(PCD) with/without Kartagener Syndrome, Heterotaxy, HLHS, WBS, Carpenter Syndrome 2 
(CRPT2), Acrocallosal Syndrome (ACLS), and Polycystic Kidney Disease 1 (PKD1).  A more 
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complete table of attributed human disease identified in mouse models of the ENU screen is 
described in Appendix A.4, Table 2.2.c. 
2.2.4 Selected Curated Mutant Lines 
Detailed analyses of the two curated lines are presented below.  They have been selected based 
on their potential research/clinical significance, characteristics that are ideal for the scope of this 
thesis discussion, and/or this author’s personal involvement in their curation. 
2.2.4.1 Line 1702 (Megf8 and Cml5) 
Mutant Line 1702, nicknamed “TLC”, is a mouse model for the human disease, 
heterotaxy.  Screenshots of mutant line 1702 as represented on the ENU database are in 
Appendix B.2.1, Figures 2.2.4.1.a-c (available with login at 
http://apps.devbio.pitt.edu/LabENU/MutantLines/Details/2377).  Line 1702 line has two 
overlapping phenotypes, each of which attributed to homozygous mutations in different genes 
with missense mutations: Megf8 (7qD3; c.442A>G:p.N148D) and Cml5 (6qC3; 
c.289A>T:p.I97F).  Two mutants, e.g. 1702-003-2 (Cml5) and 1702-007-1 (Megf8), in this line 
have been whole exome sequenced.  A list of all 1702 mutants and the corresponding unique IDs 
and genotypes can be seen in Appendix B.2.1, Figure 2.2.4.2.a.  Mutants homozygous for both 
mutations have not been identified.  Appendix B.2.1, Figure 2.2.4.1.b. depicts the complete 
catalog of homozygous mutations recovered by WES for both mutants of line 1702. 
Cardiovascular phenotype includes CHD associated with heterotaxy: dextrocardia, 
DORV, Taussig-Bing type DORV, muscular VSD (mVSD), AVSD, and coronary fistula.  
Noncardiovascular phenotype includes situs anomalies associated with heterotaxy including 
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dextrogastria and right lung isomerism; omphalocele and gastroschisis are also observed.  The 
Fyler codes annotated to the above summative diagnosis can be seen below in Figure 2.2.4.1.c. 
Images and videos from four mutant samples are published on MGD. A screenshot of these 
images and their specific order can be found in Appendix B.2.1, Figure 2.2.4.1.d.   
 
Figure 2.2.4.1.c. ENU database screenshot of Fyler codes, summative diagnosis, and human disease model  
for line 1702 
(a) MGD Publication 
Screenshots of the entry page for line 1702 (re-identified as “Megf8b2b1702clo”) as 
represented on MGD are in Appendix B.2.2, Figures 2.2.4.1.e-g (Megf8b2b1702clo URL: 
http://www.informatics.jax.org/allele/key/820747).  All 16 images depicting the phenotype for 
Megf8b2b1702clo mutants can be accessed by clicking the link next to “Show the [16 image(s)]” on 
the right side of the “Nomenclature” panel as seen in Appendix B.2.2, Figure 2.2.4.1.e.  The 
“Nomenclature” panel describes the general information for the line, such as symbol, name, MGI 
ID, synonym, and gene information.  “Mutation details” for Megf8 may be found in the 
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“Mutation Description” panel.  Cml5 gene and mutation information is pending upload.  An 
expansion of the MP phenotype terms annotating the summative diagnosis of Megf8b2b1702clo is 
shown in Appendix B.2.2, Figure 2.2.4.1.f.   The summative diagnosis and human disease model 
of Megf8b2b1702clo are also included in free-text in the “Notes” section with the Fyler codes—as 
annotated in the ENU database during curation (Appendix B.2.2, Figure 2.2.4.1.g.).  External 
resources, such as a link to IMSR for ordering mice, and references are also provided.   
(b) Previously published data 
MEGF8 is a known and well-established causative gene for Carpenter syndrome 2 
(CRPT2), which is a subtype of Carpenter syndrome.  Carpenter syndrome is a rare, genetically 
heterogeneous autosomal recessive disorder belonging to a group of disorders known as 
acrocephalopolysyndactyly (ACPS) and characterized by craniosynostosis (e.g. acrocephaly or 
pointed cranial configuration), polysyndactyly, obesity, and various CHD100–103.  The most 
commonly associated CHD include VSD, ASD, TGA, PDA, PS, and TOF18,102.  It has two 
segregating subtypes depending on the affected gene: Carpenter Syndrome 1 (CRPT1), also 
known as acrocephalopolysyndactyly type II, is due to mutations of Ras-associated protein 
RAB23 (RAB23, 6p11.2) and CRP2 is the consequence of mutations of multiple epidermal 
growth factor-like domains 8 (MEGF8, 19q13)100,101,103.  In general, the phenotype of CRPT2 is 
similar to CRPT1 or classic Carpenter Syndrome with the exception of its notable association 
with laterality defects, such as situs inversus, dextrocardia, and TGA, as well as milder 
craniosynostosis101.   
MEGF8 is involved in cell adhesion and receptor-ligand interactions and has been 
implicated in the regulation of left-right patterning, which coincides with the prevalence of 
lateralization defects and complex CHD in CRPT2101,104.  Previous mouse models of Megf8 
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recovered from an ENU mutagenesis screen have been described as having complex CHD and 
abdominal/thoracic organ situs anomalies associated with heterotaxy as well as preaxial 
polydactyly104.  MEGF8 is a highly evolutionary conserved gene as mutations in across species, 
e.g. human, mouse, and zebrafish, have shown similar laterality phenotypes101,104.  In this ENU 
screen, homozygous missense mutations in Megf8 have been previously recovered in another 
laterality line (line 288, c.3641A<T:p.N1214I).  The phenotype of line 288 includes CHD 
associated with heterotaxy, namely dextrocardia, TGA, DORV, AVSD and VSD, as well as cleft 
palate, micrognathia, and abdominal and thoracic situs anomalies (e.g. malaligned sternal 
vertebra, dextrogastria, and pulmonary isomerism).   The current MGD human disease model 
entry for Carpenter Syndrome 2 annotates Megf8b2b288clo as a relevant mouse model and provides 
a direct link to the mouse page for interested viewers (CRPT2 MGD URL:  
http://www.informatics.jax.org/disease/614976).  A screenshot of the page can be seen in 
Appendix B.2.2, Figure 2.2.4.1.h. 
RAB23, which is associated with CRPT1, encodes an essential negative regulator of the 
sonic hedgehog (SHH) signaling pathway that is established in cranial suture and neural tube 
development as well as neuronal patterning100,105,106.  Mice with homozygous ENU induced 
Rab23 mutations die in utero from exencephaly and exhibit polydactyly and eye defects (Rab23 
MGD URL: http://www.informatics.jax.org/marker/MGI:99833).  Open brain (opb) mice with 
homozygous Rab23 mutations have neural tube defects, abnormal axial skeletal morphology, 
preaxial duplication, and anophthalmia (Rab23opb MGD URL: 
http://www.informatics.jax.org/allele/key/1148). 
Currently, only one Megf8 knockout mouse, Megf8tm1.1Ddg (BALB/cJ background), has 
been reported on MGD (Megf8tm1.1Ddg URL: http://www.informatics.jax.org/allele/key/842020).  
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The associating phenotype comprises of complete lethality by E16.5, laterality-related CHD, 
abnormal neuron/axon morphology, skeletal anomalies, severe edema, and polydactyly94.   There 
has yet to be a knockout model produced through the IKMC Project (Megf8 knockout model 
progress accessible at 
http://www.mousephenotype.org/martsearch_ikmc_project/martsearch/ikmc_project/94209).   
Homozygous and compound homozygous MEGF8 mutations have been described in four 
patients with CRPT2101. 
Whereas Megf8 has been relatively well characterized as a regulator of left-right 
patterning, mutations in camello-like 5, Cml5, have not been reported before in literature. There 
is no known human ortholog of Cml5 (from UCSC BLASTP hit).  Popsueva et al. implicated 
Xcml (Xenopus ortholog of Cml5) in cell-adhesion through modification of the cell surface and 
extracellular matrix proteins in the secretory pathway107.   Overexpression of Xcml in Xenopus 
results in growth retardation due to reduced blastomere adhesion and inhibition of 
grastulation107.  There is no current research on the effects of deficiencies or mutations altering 
gene function of Cml5.  No mouse model of Cml5 is available through by either MGD (Cml5 
MGD URL: http://www.informatics.jax.org/marker/MGI:1916299) or the IKMC Project (Cml5 
knockout model progress accessible at 
http://www.mousephenotype.org/martsearch_ikmc_project/martsearch/ikmc_project/86744). 
(c) Significance of screen findings 
The CHD-heterotaxy phenotype of line 288 is similar to that of line 1702.  However, the 
abdominal wall defects and oligodactyly found in line 1702 mutants homozygous for Megf8 
mutations are absent in line 288.  This discrepancy may be explained by the location of the 
missense mutation along the gene.  Evidence suggests that residual Megf8 function is essential 
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for life in mice101.  Since the misssense mutation in line 288 is located more C-terminus of the 
protein than line 1701 (i.e. N1214I compared to N148D) perhaps more residual function of the 
protein is preserved, resulting in an attenuated phenotype or that mutating the amino acid 
asparagine (N) to isoleucine (I) as compared to aspartate (D) is less deleterious to protein 
function as both N and I have similar neutral pI while D is an acidic amino acid.  The findings 
that line 288 mutants were recovered alive whereas line 1702 mutants were harvested as embryos 
(average at E15.5) further support this hypothesis.  Another explanation could be the unknown 
effects of each line’s background mutations or other genetic interactions/modifiers, which could 
be explored in further genetic study.  
CRPT is highly variable, even within the same family, but almost universally presents 
with craniosynostosis and some form of polysyndactyly102.  CHD is an associated phenotype in 
up to 50% of cases and is not considered a cardinal feature for clinical diagnosis100–102,108.  
Neither line 1702 nor line 288 exhibits craniosynostosis and only the line 1702 mutants have 
oligodactyly.  Therefore, although line 1702 is associated with CRPT2 based on the causative 
gene, it is not fully representative as a human disease model.  Furthermore, the Megf8tm1.1Ddg 
knockout model does not present with craniosynostosis.  Megf8 in mice may be implicated in 
additional pathways besides those that are to its human ortholog; there also may be species-
specific role and importance of Megf8 in early development that clarifies this phenotype 
difference.   
Mutations in mammalian Cml5, which is a novel discovery, may contribute to the 
understanding of the complex pathways involved in CHD morphogenesis—particularly left-right 
patterning and cell-adhesion.  Given the limited knowledge on its gene function, Cml5 may be 
indicated in cell-adhesion and a regulatory role in the secretory pathway.  This suspected cellular 
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function may explain the phenotypic overlap observed with Megf8 mutants in line 1702 as Megf8 
is also involved in cellular trafficking.  Protein products of Megf8 and Cml5 may interact along 
the same pathway.  Within the schema of laterality defects, Cml5 may have a direct or indirect 
role in cilia pathways.   
Line 1702 is curated primarily as a heterotaxy model but could be utilized to clarify the 
development of CHD in CRPT2 by the differential function of Megf8 in mutant mice.  Phenotype 
comparisons of line 1702 Megf8 and Megf8tm1.1Ddg mutants may achieve fuller characterization of 
Megf8.  Deep phenotyping analysis of the nuanced phenotype differences between line 1702, line 
288, and Megf8tm1.1Ddg, could suggest genotype-phenotype correlations as well as possible 
interacting gene pathways or modifiers.  This could be used to better personalize patient care and 
improve clinical management, e.g. evaluations for abdominal wall defects (prenatal) as compared 
to orofacial clefts (pre- or post-natal).  Accordingly, the elucidation of the molecular pathways 
contributing to or shared with craniosynostosis could be further clarified.  Researchers interested 
ciliopathies and laterality may also utilize line 1702 as a potential model.  Lastly, as more data 
about Cml5 accumulates, a human ortholog may be identified.   
2.2.4.2 Line 2407 (an Adamts6 line) 
Mutant Line 2407, nicknamed “Rory”, belongs to a collection of lines attributed to 
Adamts6 mutations, including seven other curated and MGD-published lines: 1879, 2029, 2182, 
2187, 2405, 2228, and 2744.  Older lines were originally curated independently.  All eight lines 
resemble the same phenotypic spectrum, which is described below, and are now curated 
according to an agreed upon Adamts6 template.  Older lines were reviewed and updated on both 
the ENU database and MGD.  Line 2407 will serve as the representative Adamts6 line for this 
discussion.  Screenshots of mutant line 2407 as represented on the ENU database are in 
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Appendix B.3.1, Figures 2.2.4.2.b-c (available with login at 
http://apps.devbio.pitt.edu/LabENU/MutantLines/Details/3097).  Mutants are homozygous for 
nonsynonymous, missense mutations in Adamts6 (13qD1, c.447C>G:p.S149R).  Annotation of 
the pathogenic mutation on the mutant line page is depicted in Figure 2.2.4.2.a.  A list of line 
2407 mutants and the corresponding unique IDs and genotypes can be seen in Appendix B.3.1, 
Figure 2.2.4.2.b.  
All Adamts6 lines have an identical summative diagnoses and Fyler codes.  To formulate 
a consistent and representative diagnosis for these lines, samples across every line were first 
grouped according to known or unknown Adamts6 genotype.  Next, cardiovascular and 
noncardiovascular phenotypes were cataloged and percentages calculated for the presence of a 
specific feature averaged across its genotype group.  A panel of experts prioritized phenotypes 
that were observed in more than 45% of the genotyped mutants in order to determine which 
should be included.  CHD phenotypes that have a similar pathogeneses, e.g. overriding aorta and 
DORV or different VSD types and AVSD, were assessed collectively during this consideration.  
Review of mutants confirmed that each line had at least one representative sample with the 
nominated phenotypes before final curation of the Adamts6 summative diagnosis.  The statistical 
summary for the Adamts6 phenotypes is illustrated in Appendix B.3.1, Figure 2.2.4.2.d  
The final Adamts6 summative diagnosis for the cardiovascular phenotype comprises of 
overriding aorta/DORV with VSD (subaortic, perimembranous, and muscular), AVSD, and 
biventricular hypertrophy.  The Adamts6 noncardiovascular phenotype includes abnormal flexure 
of the hindlimbs, hydrops, midline fusion defect of the sternal vertebra, hypoplastic thymus, 
short snout, and cleft palate.  The Fyler Codes annotated to the summative diagnosis can be seen 
below in Figure 2.2.4.2.a.  Images and videos from four mutant samples are published on MGD.  
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A screenshot of these images and their specific order can be found in Appendix B.3.1, Figure 
2.2.4.2.c  
 
Figure 2.2.4.2.a. ENU database screenshot of mutation information, Fyler codes, and summative diagnosis for 
Adamts6 line 2407 
(a) MGD Publication 
Querying for “Adamts6” in MGD will retrieve results for seven of the eight Adamts6 
lines recovered in the ENU screen as can be seen in Appendix B.3.2, Figures 2.2.4.2.e.  At the 
time this dissertation was written, line 2744 had been uploaded to MGD and in queue for 
publication.  Screenshots of the entry page for line 2407 (re-identified as “Adamts6b2b2407clo” on 
MGD) as represented on MGD are in Appendix B.3.2, Figures 2.2.4.2.f-h. (Adamts6b2b2407clo 
MGD URL: http://www.informatics.jax.org/allele/key/842094).  All 27 images depicting the 
phenotype for Adamts6b2b2407clo mutants can be accessed by clicking the link next to “Show the 
[27 image(s)]” on the right side of the “Nomenclature” panel as seen in Appendix B.3.2, Figures 
 61 
2.2.4.2.f.  “Mutation details” for Adamts6 may be found in the “Mutation Description” panel.  
An expansion of the MP terms annotating the phenotypes described in the summative diagnosis 
of Adamts6b2b2407clo is shown in Appendix B.3.2, Figures 2.2.4.2.g.  The summative diagnosis 
Adamts6b2b2407clo is also included in free-text in the “Notes” section with the Fyler Codes—as 
annotated in the ENU database during curation (Appendix B.3.2, Figures 2.2.4.2.h.).  External 
resources and references are also provided. 
(b) Previously published data 
Adamts6 is a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin 
type 1 motif located on chromosome 13 in the mouse genome99.  It belongs to a family of twenty 
proteinases, ADAMTS (ADAM with thrombospondin-1 type repeats).  Dysregulation of 
ADAMTS function contributes to cancer development and progression, including lung, breast, 
colorectal, pancreatic, and prostate98,109,110.  Although its function of is not well understood, 
Adamts6 has been implicated in breast carcinoma as well as pituitary tumorigenesis99,111,112.  
Moreover, a missense variant in ADAMTS6 (c.455T>G; p.Val152Gly) associated with 
malignant melanoma has recently submitted into the NCBI ClinVar database.  A new Gene Card 
entry also associated ADAMTS6 with retinitis, or inflammation of the retina, perhaps in a similar 
role as Adamts1 proteins110 (http://www.genecards.org/cgi-bin/carddisp.pl?gene=ADAMTS6).  
Adamts6 and other members of the ADAMTS family are also involved in cell adhesion, 
signaling, and regulation of the extracellular matrix (ECM)98,99.  The precise regulation of the 
ECM is critical for normal heart morphogenesis110,113.  Studies have shown that ADAMTSs are 
essential for ECM homeostasis and protein processing; disruption of these proteinases has been 
associated with CHD109,110,113,114.  Specifically, Adamts1 and Adamts9 are essential for AV 
cushion maturation, trabeculation, and OFT development113,115.  Adamts1 has also been shown to 
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inhibit angiogenesis109,115.  Moreover, Adamts1 mouse studies have implicated its role in 
organogenesis, especially of the kidneys and female reproductive organs, and growth 
retardation110,113.  Mice with heterozygous mutations in Adamts9 exhibited syndactyly in addition 
to CHD of the aortic wall, valvulosinus, valve leaflets, and ventricular noncompaction109,116.  
In general, the ADAMTS proteins are highly expressed in connective tissues, such as in 
cartilage and tendon98,110,114.  Members of ADAMTS, notably ADAMTS1, ADAMTS4, and 
ADAMTS9, are involved in angiogenesis, atherosclerosis, thoracic aortic aneurysms and 
dissections, and tissue destruction in vascular diseases110,115.  ADAMTSs have been associated 
with the pathology of specific human diseases.  For instance, ADAMTS2 and ADAMTS10 are 
associated with two autosomal recessive connective tissue disorders, Ehlers–Danlos syndrome 
type VIIC (also known as dermatosparaxis) and Weill–Marchesani Syndrome 1 (WMS1), 
respectively, whereas mutations of ADAMTS13 have been found in patients with familial 
thrombotic thrombocytopenic purpura (TTP)99,110,114.  
(c) Significance of screen findings 
The function(s) of Adamts6 is not well understood.  Querying for “Adamts gene function” 
in Pubmed yielded 457 citations, where as the search phrase “Adamts6 gene function” returned 
only 11 results. Comparing the phenotypes associated with better-characterized ADAMTS 
proteinases with the phenotype of line 2407 described above, will add to understanding of 
Adamts6 function.  Diagnosed CHD features in line 2407, namely overriding aorta/DORV and 
various VSDs, partially align with those implicated in previous study of Adamts1 and Adamts9, 
i.e. anomalies of OFT and ventricular trabeculation, respectively113,115,116.  Furthermore, although 
not included in the final consensus summative diagnosis, ventricular non-compaction—also seen 
with Adamts9 knockout mice—was detected in approximately 21.1% of all homozygous 
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Adamts6 line mutants (Appendix B.3.1, Figure 2.2.4.2.d)113,116.  Similarly, abnormal flexure of 
the hindlimbs and midline fusion defects of the sternal vertebra, identified in 94.7% and 47.4% 
of Adamts6 line mutants, respectively, further support the localization and role in the pathology 
of ADAMTS proteins in connective tissues.    
The Adamts6 lines presented with a wide-range of phenotypes and of different 
frequencies.  This variable expressivity imitates the variability often observed even within a 
family with CHD or established syndromes in which CHD is a feature. A high-resolution 
investigation of the genetic profiles of these mutants could elucidate other genes or modifiers 
contributing to the development of specific CHD.  It could also enhance the current relationship 
of cardiac morphogenesis and ECM regulation.  Cross-comparison of the Adamts6 lines with the 
same mutation and those with different mutations may be significant in genotype-phenotype 
correlations.  Analysis of genotype-phenotype correlations both within the ADAMTS family and 
connective tissue disorders, could improve diagnostic and therapeutic developments.  
Understanding the role of Adamts6 in mice, could also nominate other areas for clinical 
evaluation, such as screening for certain cancers.  Thus, Adamts6 lines recovered in the ENU 
screen could serve as a good model for translational research.    
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3.0  DISCUSSION OF SCREEN PROTOCOL  
In order to meet to increasing requirements of an expanding research program demands, curation 
protocol needs to be dynamic, but yet standardized to eliminate curator variability.  It must be 
continually improved and adaptable to changes as the study progresses.  The current ENU 
curation protocol is an improved version of the original created in 2011.  It has been modified in 
order to the meet the increasing needs ENU mutagenesis screen.  The dynamic nature of not only 
the curation, but also of the entire project, has lent itself to the success of the screen.  
Communication has been an essential component to the development and characterization of 
nearly 200 mutant lines, representing a broad spectrum of CHD—from PDA to HLHS—as well 
as striking noncardiovascular phenotypes such as ectopia cordis, bilateral kidney agenesis, and 
chiari malformations without and without complex CHD.  The majority of the phenotype 
analysis is completed manually, which has often been the rate-limiting step in the curation 
process.  As illustrated in Figure 1.2.3.1.b., the bottlenecks in the translational research 
continuum have moved downstream from the once time-consuming construction of an 
organism’s genetic profile to phenotype analysis and data integration.  Effort needs to be made to 
facilitate phenogenomics and data integration in order to accelerate translation of basic 
biomedical science discoveries to clinical application, and vice versa.   
For an example, the ENU screen has experienced practical limitations on the speed to 
which it can conduct deep phenotyping of the all its mutant mice.  Although it has achieved great 
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characterization of CHD phenotypes, the thoroughness of a multi-tiered imaging strategy has its 
disadvantages as stated above.  Thus, the curation protocol must be further improved and 
modified to expedite the screen workflow as well as augment internal database function.  The 
following sections will discuss the efficacy of the current protocol within the B2B translational 
paradigm as well as its utility at the community and public health care levels.  The importance of 
ontology harmonization and database interoperability for the future progress of biomedical 
research will also be addressed.   
3.1 MEETING THE GOALS OF TRANSLATIONAL RESEARCH  
Briefly, the primary goal of translational research in the scope of this study is to improve public 
healthcare of CHD patients by accelerating the new discoveries made in the laboratories to 
clinical research, care, and practice.  Translational research programs, such as B2B, provide an 
environment that fosters dynamic, multidisciplinary collaborations between basic science and 
clinical researchers.  The design of the NHLBI B2B collaborative research program overcomes 
many of the translational blocks described by IMCRR (see Figure 1.2.1 in section 1.2.1).  
Frequent and direct communication as well as transparency between consortia provides 
researchers access to resources and expertise not otherwise available.  Public access to 
continually updated discoveries encourages further collaborations with outside researchers and 
new data from which to generate novel hypotheses.   
The ENU screen at the University of Pittsburgh has significantly contributed to the 
understanding of CHD and has provided disease models for which additional studies.  The wide-
range of CHD observed and the multitude of noncardiovascular phenotypes characterized in 
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almost every organ system demonstrate the pervasive nature of CHD pathology as well as 
highlight the variable expressivity of CHD even within inbred strains of laboratory mice.  The 
sophisticated, state of the art combination of imaging and genetic methodologies utilized has 
been powerful in describing subtle and complex CHD at high resolution as well as in validating 
the pathogenic mutation attributing to its manifestation.   
Of the 184 mutant lines curated on MGD, 33.7% are associated with a human disease and 
53.2% have an identified pathogenic mutation in one of the 68 unique genes (see Table 2.2.3.b in 
section 2.2.3).  In translational research, these phenotypically and genetically well-characterized 
mouse models may provide insights to relationship between CHD to other diseases, such as those 
in a syndrome or gene family, as well as phenotypes in model organisms for which there is only 
partial but significant overlap of symptoms.  Having novel or better mouse models of disease 
would be very useful for therapy and drug development.  Phenotype-genotype information can 
inspire future research and advance objectives across the translational continuum.  Each 
established human and mouse gene-disease/phenotype correlation or relationship becomes a 
unique hypothesis that can be utilized and tested in a variety of ways. 
The discoveries made in translational research programs are transparent to the research 
and clinical communities.  In the spirit of collaborative research, findings are published online 
prior to submission for journal publication.  For example, the B2B program believes that the 
potential to improve healthcare of CHD is of utmost importance.  Discoveries should not be 
delayed by the need for authorship.  In fact, physicians have frequently contacted Dr. Lo about 
their patients with CHD who have directly benefited from open access to curated mouse models 
in variant classification of NGS results in genes not yet reported in literature but for which a 
mutant line was recovered in the ENU screen (personal communication with Dr. Lo).  In these 
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instances, the fruition of basic science research in the translational continuum is realized with 
clear direct effect on patient care.  With a high degree of confidence, these clinicians can provide 
an answer for their patients, especially in terms of family planning, as well as nomination for 
other organ system evaluations.   
Regular, active communication is paramount in translational research.  In addition to 
weekly ENU meetings during which team members update the group on their progress, a 
monthly curation meeting is held with in-house experts of their respective modalities as well as 
pediatric cardiologists from Children’s Hospital of Fudan University (Shanghai, China) and 
Children’s National Medical Center (Washington D.C., VA).  Mutant lines ready for final review 
are discussed and approved for MGD upload during this time.  A monthly conference call is also 
conducted in order to comment on the technical matters of the B2B project, such as database 
design, grant reports, and/or representation of data/mouse models, with collaborators from JAX, 
NERI, Children’s National Medical Center, and NHLBI.  These meetings ensure all groups are 
informed of the latest developments, which minimizes redundancies and time lost in static, 
written correspondence.  Thus, it is evident that B2B is an exemplary, successful translational 
research program upon which future collaborative endeavors should emulate. 
3.2 LIMITATIONS 
Even with the success of B2B, there are limitations to the current transfer and translation of data 
in the mutagenesis screen protocol and curation.  While it was this author’s responsibility to 
manage the overall ENU curation process, within each modality, independent annotation of data 
into  the  database  is  necessary  (see Figure 2.2.1 in section 2.2.1).  These  annotations  are often
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free-text observations that then need to be translated into a pre-determined set of defect codes.  
The set of defect codes is not shared across modalities within the database; each group has its 
own vocabulary, which prevents computational comparisons for cross-modality consistency 
during curation and analysis.   
An examination of the EFIC codes in the ENU database listed in Appendix B.4, Table 
2.2.1.2 shows spelling errors (blue text), duplicate entries (red boxes), ambiguous/synonymous 
terms (italicized), and limited depth—all of which interfere with accurate translation and 
interpretation of the data without heavy reliance on free-text notes.  For instance, there are 
twenty-five redundant EFIC terms (red boxes). “Pulmonary atresia” is represented three times—
twice in the same general “Cardiovascular” category and once more under “Outflow Tract”. One 
entry for “pulmonary atresia” is misspelled (blue text).  This could result in inconsistent 
annotation and data retrieval depending on which “pulmonary atresia” is marked.  Redundancies 
may also occur because of ambiguity or annotator preference of synonymous terms (italicized).  
An experienced user understands that “ventricular myocardial non-compaction” and “spongy 
ventricle walls” are relatively synonymous, but a computer algorithm would not intuitively 
reason the two as synonyms.  In fact, there are three synonymous EFIC codes that refer to “non-
compaction”.  Similarly, “transposition of great arteries” and its acronym “TGA” are both 
included, as are “double IVC” and “dual IVC”.  As demonstrated with the variability of results 
that can be returned in OMIM, synonymous, yet incongruent, phrases are not naturally amenable 
to computer retrieval in a non-ontological system (see Table 1.3.1.1 in section 1.3.1.1).   
In order to reduce user error and variability, a formal annotation (e.g. common, 
standardized codes) system should be used across modalities.  The defect codes in the current 
ENU database need to be updated in order to improve in-house analysis of the phenotypic data.  
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Synonyms or related CHD phenotypes should be semantically linked in the underlying structure 
of the defect code.  For instance, if defect codes are defined independently as well as in terms of 
each other, then when a code is not formally included, e.g. “supravalvular aortic stenosis”, it will 
still be retrieved as a result in related queries, e.g. “aortic (valve) stenosis”.  The feasibility of a 
complex ontology for the needs of the in-house ENU database is unlikely, but modeling the 
current system as an abridged version could greatly expedite the curation process as well as 
interrogation of annotated data.  Revising database design will be labor intensive and down-
stream effects may be not be readily anticipated, however.  For example, changes in the defect 
coding system may not be backward compatible, and therefore may have the potential of further 
data loss and necessitate extensive manual validation. 
Moreover, the formal annotation system should be emendable so that new defect codes 
could be added as needed, such as the recent addition of “tetralogy of fallot” in the EFIC defect 
codes.  This flexibility enhances the screen’s ability to describe and represent various CHD 
phenotypes.  Otherwise, an annotator may either rely on his free-text notes to describe the 
phenotype or choose a closely-related, but not synonymous, term.  Inconsistent and imprecise 
defect coding could impact data retrieval in the current system and hinder proper curation of a 
phenotype as highlighted below in section 3.2.1.   
Lastly, during translation from free-text observations to defect codes, information may be 
lost, inconsistently annotated, and/or misrepresented without meticulous manual validation.  This 
requires repeated confirmation requests with experts and extensive man-hours spent on cross-
referencing each sample as well as waiting for responses from electronic communication.  These 
efforts could otherwise be employed in higher-level study if querying the ENU database were 
systematic and its phenotypes annotation structured like ontology.  Moreover, gaps in the ENU 
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database limit the potential in-house utility for screen-wide comparative analysis, data-mining, 
identification of relevant application, or inspiration for novel study.  
3.2.1 Example: Supravalvular Aortic Stenosis  
The limitations discussed above are illustrated by the curation of line 370.  Supravalvular aortic 
stenosis (SVAS) was consistently observed in this line.  SVAS is a characteristic and prevalent 
phenotype for WBS; therefore, line 370 was curated as a prospective disease model on MGD 
(Loxb2b370.2clo URL: http://www.informatics.jax.org/allele/key/817300).  Although the final 
curation of line 370 emphasizes SVAS, both necropsy and EFIC defect codes do not include 
“supravalvular aortic stenosis”.  Consequently, in some samples for line 370, no defect code was 
annotated whereas in other mutants, the code for “aortic valve stenosis” was chosen as the 
closest representation.  “Aortic valve stenosis” and “supravalvular aortic stenosis” are not 
equivalent and translating the two terms as such misrepresents the CHD phenotype as well as the 
line itself, i.e. not recognizing it as a relevant model for WBS.   
In addition, if researchers were interested in the phenotype “supravalvular aortic stenosis” 
or a model for WBS, line 370 may not be retrieved in an in-house query as the database is 
restricted to only mining annotated defect codes in keyword searches.  For instance, querying for 
“supravalvular aortic stenosis” retrieved zero results whereas the phrase “aortic stenosis” failed 
to return mutants from line 370 that were coded with the term “aortic valve stenosis”, and vice 
versa.   
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3.3 PROPOSAL 
Symbolized as red circles in Figure 2.2.1 in section 2.2.1, translation of data occurs at multiple 
points throughout the ENU screen.  At each of these points, there is the potential for data 
corruption—ranging from a complete loss (e.g. no translated equivalent provided) to disruption 
of the original and desired meaning.  To minimize significant loss of data, ENU screen workflow 
has successfully incorporated a panel review of all data at each modality and multiple times 
throughout the curation process.  Moreover, curated lines on MGD are not static and can be 
continually revised when new or updated data is produced.  Nevertheless, screen efficiency could 
still be improved in the ENU database.  First of all, database defect codes should be expanded, 
standardized across modalities, and edited for redundancies.  Secondly, representation of defect 
codes should be amenable to computational retrieval and interrogation in order to facilitate 
multi-leveled comparative analysis, e.g. within and across lines, as well as between modalities.  
3.3.1 Future Direction 
The NHLBI B2B program and the ENU screen have significantly benefited the CHD research 
and patient community.  The innovative and collaborative paradigm espoused by the program 
has overcome many of the translational blocks that persist in translational research as a whole. 
Discoveries within the paradigm have efficiently translated across the disciplines and individual 
projects.  However, to promote translation of the B2B data into public practice and heath-care 
policy, its databases need to be user-friendly and its data represented as formalized, standardized 
ontologies.  This will involve integration and dissemination of enormous volumes of complex 
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genotypic and phenotypic data that is intrinsically compatible and tractable to both 
computational analysis and retrieval.   
In curation of its mouse model data, MGD has aligned MP terms to the IPCCC Fyler 
Code.  Used in conjunction, the two vocabularies are able to properly characterize CHD as seen 
in mice and cross-reference the phenotypes so searches in either lexicon return with 
comprehensive results.  The Nomenclature Working Group (NWG), also known as the 
International Working Group for Mapping and Coding of Nomenclatures for Paediatric and 
Congenital Heart Disease, created the IPCCC in 2005117.  The NWG had collaborated with the 
International Congenital Heart Surgery Nomenclature and Database Project of The European 
Association for Cardio-Thoracic Surgery (EACTS) and The Society of Thoracic Surgeons (STS).  
In order to create the IPCCC, the NWG cross-mapped a common nomenclature, which was 
developed and adopted by the EACTS and STS in 2000, with the nomenclature used by the 
European Paediatric Cardiac Code of the Association for European Paediatric Cardiology117.   
The IPCCC is continually updated by the International Society for Nomenclature of Paediatric 
and Congenital Heart Disease and focuses on nomenclature of both procedures and 
complications associated with interventional cardiology, namely concerning pediatric and 
congenital CHD118.  The IPCC is currently being utilized by the EACTS and STS databases in 
order to jointly analyze the outcomes of surgical CHD patients. 
Within MGD and the B2B consortia, the translational gap between human phenotypes 
and its mouse ortholog is largely insignificant.  However, while MP terms are a formal ontology, 
the Fyler Code is a classification system akin to ICD-9, which makes harmonization of the 
nomenclatures less complicated than if mapping two ontologies and all the complex, semantic 
relationships included within.  A possible answer is the development of a relational ontology 
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such as OBO’s CARO: all OBO ontologies, including the MP terms and subsequently the linked 
Fyler Codes, can be aligned together more easily once mappings are created.  New ontologies 
would be designed to model the CARO framework as well.  The next step for research-wide 
interoperability and integration would require adoption of a master ontology mapping system by 
autonomous databases, which in turn would allow for all data to be amassed at a centralized 
database hub.  This hub would organize all the federated data into a cohesive, intuitive catalogue 
of searchable research for all domains in the translational research continuum.  A harmonious, 
formal ontology network will ensure the retrieval of relevant and inclusive information. 
3.3.2 Going International  
The HGP was one of the first and most successful international, large-scale biology project119,120.  
The $3 billion, 15-year long project exemplified integrated, cross-disciplinary efforts across on a 
global scale.  Through international participation in a collaborative system, the HGP completed 
its goals two years ahead of schedule and below budget costs119,120.  It involved twenty centers 
from six countries: China, France, Germany, the United Kingdom, Japan, and the United States, 
each of which was responsible for the mapping and sequencing of its part of the genome119.  The 
five largest centers, which are informally known as the “G5”, included the Sanger Institute, the 
U.S. Department of Energy (DOE) Joint Genome Institute, as well as three NIH-funded centers: 
Baylor College of Medicine, the Washington University School of Medicine, and the Whitehead 
Institute, were the primary project coordinators119.  
The structure of the B2B program mirrors that of the HGP; both involve regular 
conference calls and meetings as well as immediate release of data or updates to the public.  The 
HGP, in fact, advocated the practice o f making data immediately available in readily accessible 
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databases as a means to advance research and collaboration120.  Moreover, the success of both 
endeavors was founded on an integrated network of independent centers striving towards a 
shared objective. Developing the B2B program into a network of consortium involving multiple 
countries and spanning different continents is necessary to promote the progress and utility of 
CHD research.  
In order to broaden the scope of the B2B program to an international scale while 
preserving its advantages in overcoming the blocks existing in the translational continuum, it 
should continue to model after the HGP.  The B2B program collaborators interact at primarily a 
scientist-to-scientist level, and if expanded globally, should also continue to do so.  This level of 
interaction is similar to that of the HGP, which helped circumvent the politics and inefficiencies 
of communicating through government health agencies or state representatives.  Frequent 
meetings and public updates should be maintained.  Project funding should be achieved at 
multiple levels to provide financial stability as well as ensure quality and accountability.  These 
levels include independent grants, national agencies like the NIH, and international 
organizations, such as the Wellcome Trust.  The data may remain the current systems, but ideally 
should transition into a global, primary database. 
To date, there is no principal database for CHD.  Those that exist are either segregated or 
selectively focused on adults, surgery/clinical patients, and/or general cardiology.  For instance, 
internationally there are the European Society of Cardiology (ESC) and the EACTS.  The latter 
developed the European Congenital Heart Defects Database (ECHDD) for risk stratification as 
well as the improvement of CHD surgery-related mortality and morbidity; the ECHDD is now 
known as the EACTS Congenital Database (accessible at http://www.eactscongenitaldb.org/).  
Similarly, in the U.S., the STS created the STS National Database, which houses information for 
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adult cardiac, general thoracic, and congenital heart surgeries (accessible from 
http://www.sts.org/national-database).  Expanding and applying the B2B program, which has 
followed the success of HGP design, could provide the model and basis for an international CHD 
translational research database that spans basic science, clinical, as well as health policy 
interests. 
3.4 SIGNIFICANCE 
Genotype-phenotype correlations have impact at both the individual and population level.  With 
the common utilization of microarray and the growing popularity of WES, interpretation of 
genetic testing results will be increasingly important.  These tests frequently return results that 
are difficult to classify due to limited knowledge on the phenotypic consequence of genomic 
variation.  However, mutagenesis screens coupled with IKMC can potentially provide a model of 
human disease for every protein-coding gene in the mouse genome.  Notably, the ENU screen 
has recovered genes that have not been associated with disease or reported before in literature.  
Incorporated into the translational research paradigm, this data could fill the gap between genetic 
testing and interpretation of ambiguous results.  For mutant lines with genes that have been 
previously characterized, its data adds to the current understanding and provides a model for 
nuanced genotype-phenotype analysis.  The utilization of high-resolution imaging and deep 
phenotyping attributes a wealth of data that can indicate new pathways or relationships between 
CHD as well as with other phenotypes observed, e.g. ciliopathies.    
The ENU screen facilitates translational research by providing novel mouse models of 
human disease, which can be used to develop more effective therapeutic strategies and patient 
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care.  This improved paradigm for diagnosis, treatment, and ideally intervention can be 
disseminated at the community level and improve health care.  As a large portion of CHD is 
multifactorial, population-level investigations into contributing environmental factors will 
influence public health.  When adopted into the clinical practice and policy domain, it can help 
inform healthcare decisions and guideline development for CHD, which is a pervasive public 
health problem that is commonly associated with long-term health complications17,24.  These 
complications require constant surveillance121.  Moreover, patients with CHD have an increased 
risk for psychological problems24,122 and report an overall lower quality of life123,124.  Emerging 
therapies based on basic science discoveries will be vital as the CHD population survive into 
adulthood and reproduce.   
3.4.1 Genetic Counseling  
From a genetic counseling perspective, not only can the ENU discoveries aid in candidate gene 
analysis and prioritization—particularly for interpretation of genetic variations not previously 
reported in literature— but can also help guide testing choices and strategies.  Correlating a 
patient’s phenotype with a mouse model may help distinguish between the most appropriate 
panels or if a microarray/NGS should be performed.  Moreover, identification of a disease-
causing mutation can be used to discuss recurrence risk and family planning.  For a condition 
such as CHD, in which the psychological burden—particularly fear of sudden death—, a genetic 
diagnosis could help alleviate patient and family anxiety.   
Data from the B2B program can also contribute to conditions that are well-established.  
Many individuals with CHD have problems in other organ systems that suggest a specific 
diagnosis, e.g. SVAS and WBS.  In fact, often CHD is the original clinical indication.  
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Understanding the relationships between CHD and other genetic associated diseases can help 
with appropriate management, e.g. recommended screening, and earlier detection.  This will help 
genetic counselors, as well as other healthcare professionals, appreciate the subtleties of CHD, 
and facilitate timely diagnosis.  If database integration were developed, genetic counselors could 
relay frequency data—extrapolated across multiple patient populations—of certain phenotypes, 
which could affect patient perception of disease severity.  Recognizing the full phenotypic 
spectrum associated with CHD may help prevent complications or indicate other organ systems 
for medical attention at earlier stages.  It could also identify other at-risk family members who 
could benefit from evaluation. 
3.4.2 Public Health Competencies 
The B2B program demonstrates the fundamental challenges of translational research in public 
health.  This translational research model epitomizes the successes possible with dynamic 
communication and partnerships in the investigation of new insights into CHD with the common 
goal of innovative and improved clinical solutions.  In particular, effective communication and 
maintaining organizational integrity were the primarily responsibilities of the ENU screen 
curator.  The overall B2B program is a novel attempt at improving the quality and cross-
disciplinary application of CHD research.  It recognizes the translational challenges that exist 
throughout the continuum and aims to modify traditionally segregated research into a 
collaborative system.    
This thesis further exhibits the importance of careful program planning and 
implementation.  If the current segregating barriers in research persist, in part due to ontology 
and database incompatibility, then the ultimate utility of basic science data, i.e. its impact in 
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public health, is significantly diminished.  Dependence on information technology will continue 
to grow in the future; therefore, it is vital to address the aforementioned issues promptly in order 
to advance the research community’s ability to access, interpret, and apply essential data readily.  
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4.0  CONCLUSION 
Large-scale mutagenesis screens with mouse models of human disease coupled with 
advancements in genetic technologies have altered the translational research paradigm.  Research 
is no longer limited by genetic profiling, e.g. the sequencing and physical mapping, and 
generation of model organisms is facilitated by both the amenable and prolific nature of the 
laboratory mouse as well as high-throughput forward genetics, particularly ENU mutagenesis.  
The ENU screen for CHD has benefited from the recent developments in research and has 
successfully characterized over 200 mouse models of disease by implementing a multi-tiered 
imaging strategy and careful curation for publication on a widely accessible database, MGD.   
The ENU screen is a part of the NHLBI B2B program and shares its goal in transparent and 
accelerated application of basic science discovery to clinical practice.  
 While achieving its mission within the B2B program, there are inefficiencies that impede 
translation of the data to the public level.  The preferred ontologies utilized are the Fyler Code 
and MP Ontology, both of which are excellent within the defined scope, but are not easily 
aligned with those that are adopted in other databases.  Database integration will be integral in 
advancing the future of translational research, and subsequently improved public health.  
Furthermore, members of the biomedical and bioinformatics community are increasingly 
recognizing the need to harmonize the diverse ontologies used in annotation in order for the 
accumulated wealth of research data to be fully mined.  These translational gaps exist throughout 
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the infrastructure of research and compromise the efficacy as well as future of the entire 
translational research paradigm.   
While a single ontology to represent all domains is impractical, a universal reference 
ontology, upon which all others are mapped, is fundamental to the integration of translational 
research.  The ultimate goal is the development of a centralized, comprehensive database that 
serves as the primary public interface for all data collected by an integrated network of federated 
databases.  Coupled with a harmonious ontology system that transverses both species and 
domain disparities, all data relevant to a specific query can be retrieved from multiple resources 
and accessed at on a single platform.  Undoubtedly, this will accelerate progress from the bench 
to bedside, and finally, to improved personal and public health.  
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APPENDIX A 
SUPPLEMENTARY TABLES  
A.1 ONTOLOGIES 
Table 1.3.1. Domain and prefix of selected ontologies (homepage URLs are listed in notes) 
Ontology and Phenotype Codes Prefix Domain 
Adult Mouse Anatomy (AMA)A MA Mus musculus, Anatomy 
Foundational Model AnatomyB FMA Mammals; Anatomy 
Fyler CodeC 
 
Homo sapiens; Phenotype; CHD 
Human Phenotype Ontology (HPO)D HP Homo sapiens; Phenotype 
International Classification of DiseasesE ICD Homo sapiens; Disease 
International Paediatric and Congenital  
Cardiac Code (IPCCC) F 
 
Homo sapiens; CHD Phenotype 
Mammalian Phenotype OntologyG MP Mammals; Anatomy 
Open Biological and Biomedical  
Ontologies (OBO) FoundryH  
Cross-species 
Gene OntologyI GO All organisms; Gene products 
Chemical Entities of Biological InterestJ ChEBI Biochemistry 
Phenotype and Trait OntologyK PATO Phenotype 
Plant OntologyL PO Plant; Anatomy 
PRotein Ontology (PRO) M PR Proteins 
Relation OntologyN RO Relations in ontologies 
Xenopus Anatomical OntologyO XAO Xenopus; Anatomy 
Zebrafish Anatomical OntologyP ZFA Danio rerio; Anatomy 
Homepage URLs: 
 
Ahttp://www.informatics.jax.org/searches/AMA_form.shtml 
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Bhttp://fma.biostr.washington.edu 
  C http://www.ipccc.net/Download%20the%20IPCCC/DownloadM.htm 
Dhttp://www.human-phenotype-ontology.org/ 
Ehttp://apps.who.int/classifications/icd10/browse/2010/en 
Fhttp://www.ipccc.net/ 
  Ghttp://www.informatics.jax.org/searches/MP_form.shtml 
Hhttp://obofoundry.org 
  Ihttp://geneontology.org 
  Jhttp://ebi.ac.uk/chebi 
  Khttp://www.phenotypeontology.org 
  Lhttp://plantontology.org 
  Mhttp://pir.georgetown.edu/pro 
  Nhttp://obofoundry.org/ro 
  Ohttp://www.xenbase.org/anatomy/xao.do?method=display 
Phttps://zfin.org/zf_info/anatomy/dict/sum.html 
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A.2 MGD STATISTICS 
Table 1.3.1.2. Relevant MGD statistics (extracted from 
http://www.informatics.jax.org/mgihome/homepages/stats/all_stats.shtml) 
Statistics as of 22 April 2014 Total Number 
Mutant alleles in mice  37,135  
Genes with mutant alleles in mice  9,286  
Genotypes with phenotype annotations  51,438  
Human diseases with one or more mouse models  1,307  
Mouse genotypes modeling human diseases  4,348  
Mammalian Phenotype (MP) ontology terms  9,805  
MP annotations total  267,297  
Quantitative Trait Loci (QTL)  4,820  
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A.3 NHLBI B2B PROGRAM 
Table 2.1.a. Participating institutions of the B2B Consortia 
Institution Project Title 
Pediatric Cardiac Genomics Consortium (PCGC) 
Children's Hospital Boston/Brigham and  
Women's HospitalA 
Copy Number Variants for Discovery of  
Congenital Heart Genes 
The Children's Hospital of PhiladelphiaB The Genetic Basis of Conotroncal Defects 
Columbia University Medical CenterC  Molecular Approaches to Gene Identification  
in Congenital Heart Disease 
Mount Sinai School of MedicineD Genomic Studies of Secundum Atrial Septal  
Defects 
Yale UniversityE Genetic Determinants of Human Heterotaxy  
and Aortic Arch Malformation 
Collaborating PCGC Centers and Core Facilities 
Brigham and Women's HospitalF 
 Cohen Children's Medical Center of NYG 
 University College of LondonH (UK)  
 University of RochesterI 
 Children's Hospital of Los AngelesJ 
 Coriell Institute for Medical ResearchK 
   Cardiovascular Development Consortium (CvDC) 
J. David Gladstone InstitutesL The Epigenetic Landscape of Heart  
Development 
Harvard University Medical SchoolM Mapping Transcriptional Networks in Cardiac  
Development 
University of PittsburghN Modeling the Genetic Basis for Human  
Congenital Heart Disease in Mice 
University of UtahO Genome-wide Analysis of Cardiac  
Development in Zebrafish 
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Collaborating CvDC Centers and Core Facilities 
Boston Children's HospitalP 
 Children's National Medical CenterQ 
 Dana-Farber Cancer InstituteR 
 Massachusetts Institute of TechnologyS 
 University of MassachusettsT 
 Jackson LaboratoryU 
 Principal Investigator(s): 
 AJane Newburger and Christine Seidman 
BElizabeth Goldmuntz 
CWendy Chung and Dorothy Warburton 
DBruce Gelb 
EMartina Brueckner and Richard Lifton 
FChristine Seidman 
GAngela Romano-Adesman 
HJohn Deanfield and Alessandro Giardini 
IGeorge Porter 
JRichard Kim 
KDorit Berlin 
LBenoit Bruneau, Deepak Srivastava, Laurie Boyer, Katherine Pollard, Bruce Conklin, and  
Shinya Yamanaka 
MJonathan Seidman and Christine Seidman 
NCecilia Lo 
OJoseph Yost 
PLaurie Jackson-Grusby and William Pu 
QLinda Leatherbury 
RMarc Vidal 
SLaurie Boyer 
TGreg Pazour 
UJanan Eppig and Laura Reinholdt 
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Table 2.1.b. Participating centers of the Pediatric Heart Network (PHN) 
Institution Location 
Pediatric Heart Network (PHN)  
Baylor Texas Children's Hospital Houston, TX 
Cedars-Sinai Medical Center Los Angeles, CA 
Children's Health Care of Atlanta - Emory University Atlanta, GA 
Children's Hospital & Clinic St. Paul, MN 
Children's Hospital and Regional Medical Center Division of  
Cardiology 
Seattle, WA 
Children's Hospital at Montefiore Bronx, NY 
Children's Hospital Boston  Boston, MA 
Children's Hospital of New York New York, NY 
Children's Hospital of Pittsburgh Pittsburgh, PA 
Children's Hospital of Wisconsin Milwaukee, WI 
Children's Memorial Hospital Chicago –  
Northwestern University 
Chicago, IL 
Children's National Medical Center Washington, DC 
Children’s' Hospital of Philadelphia Philadelphia, PA 
Congenital Heart Institute of Florida Tampa, FL 
Ghent University (Belgium) Ghent, Flanders 
Heart Institute, Rady Children's Hospital –  
UCSD School of Medicine 
San Diego, CA 
Hospital For Sick Children (Canada) Toronto, Ontario 
Johns Hopkins University Baltimore, MD 
Medical University of South Carolina Charleston, SC 
Mt. Sinai Hospital New York, NY 
Nemours Cardiac Center Wilmington, DE 
New York Presbyterian Hospital/Weill Cornell Medical Center New York, NY 
North Carolina Consortium Durham, NC 
Prairieland Consortium Cincinnati, OH 
Primary Children's Medical Center Salt Lake City, UT 
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Stanford University Stanford, CA 
Toronto General Hospital (Canada) Toronto, Ontario 
University of Michigan Ann Arbor, MI 
University of Pennsylvania Philadelphia, PA 
Vanderbilt University Medical Center –  
Monroe Carell Jr Children's Hospital 
Nashville, TN 
Washington University in St. Louis St. Louis, MO 
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A.4 ENU SCREEN 
Table 2.2.c.  Selection of recovered genes and associated human disease from ENU screen 
Mouse 
Gene Associated Human Disease  OMIM # 
Genes with Human Disease  
 Ap2b1 Ataxia telangiectasia, cerebellar degeneration 208900 
Cxcr4 WHIM Syndrome 193670 
Dnm2 Charcot-Marie-Tooth Syndrome (CMTDIB); 606482; 
Lethal congenital contracture 5 (LCC5);  615368; 
Centronuclear myopathy 1 (CNM1) 160150 
Dync2h1 Short-rib thoracic dysplasia 3 (SRTD3) 613091 
Frem2 Fraser's Syndrome, Cryptophthalmos Syndrome 219000 
Ift140 Mainzer-Saldino Syndrome (MZSDS)A 266920 
Lrp1 Alzheimer's Disease; 104300; 
Schizophrenia 181500 
Ltbp1 Exfoliation Syndrome (XFS) 177650 
Megf8 Carpenter's Syndrome 2 (CRPT2) 614976 
Pcks5 VACTERL/VATER Syndrome 192350 
Prdm1 Devic disease; B-cell lymphoma 
 Smarca4 Rhabdoid tumor predisposition syndrome type 2 (RTPS2); 613325; 
Coffin-Siris Syndrome (CSS) 139500 
Sufu Medulloblastoma; 155255; 
Basal cell nevus syndrome (BCNS) 109400 
Ciliopathy-Related Human Disease  
 Primary Ciliary Dyskinesia (PCD) 
 
Armc4 Primary Ciliary Dyskinesia 23B 615451 
Ccdc39 Primary Ciliary Dyskinesia 14B 613807 
Dnaaf3 Primary Ciliary Dyskinesia 2B 606763 
Dnah11 Primary Ciliary Dyskinesia 7B 611884 
Dnah5 Primary Ciliary Dyskinesia 3B 608644 
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Dnai1 Primary Ciliary Dyskinesia 1 (Kartagener Syndrome) 244400 
Drc1 Primary Ciliary Dyskinesia 21B 615294 
Dyx1c1 Primary Ciliary Dyskinesia 25B 615482 
 Joubert Syndrome (JBTS) 
Cc2d2a Joubert Syndrome 9; 612285 
COACH Syndrome 216360 
Meckel Syndrome 1 (MKS1) 249000 
Cep290 Joubert Syndrome 5; 610188 
Senior-loken Syndrome 6; 610189 
Bardet-Biedl Syndrome (BBS); 209900 
Leber Congenital Amaurosis 10 (LCA10); 611755 
Meckel Syndrome 4 (MKS2) 611134 
Jbts17 Joubert Syndrome 17 614615 
Kif7 Joubert Syndrome 6; 610688 
Acrocallosal Syndrome (ACLS); 200990 
Hydrolethalus Syndrome 2 (HLS2) 614120 
Tmem67 Joubert Syndrome 6; 610688 
Nephronophthisis 11; 613550 
Meckel Syndrome 3 (MKS3); 607361 
COACH Syndrome; 216360 
Bardet-Biedl Syndrome (BBS) 209900 
 Polycystic Kidney Disease (PKD) 
Anks6 Nephronophthisis 16C 615382 
Bicc1 Cystic renal dysplasiaC 613807 
Nek8 Renal-hepatic-pancreatic dysplasia 2 (RHPD2)C; 615415 
Nephronophthisis 9C 613824 
Pkd1 Polycystic Kidney Disease 1 (PKD1) 173900 
Pkd11 DiaphanospondylodysostosisC 608022 
      
   Notes: 
  ASynonym for short-rib thoracic dysplasia 9 (SRTD9) 
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BAlso observed is Kartagener Syndrome (OMIM #244400), e.g. PCD with SIT  
CHas features of Polycystic Kidney Disease (PKD) 
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APPENDIX B 
SUPPLEMENTARY EXCERPTED DATA 
B.1 MAMMALIAN PHENOTYPE BROWSER 
 
Figure 1.3.1.2.b. MGD screenshot of MP ontology annotation summary of associated  
genotypes and references for “overriding aortic valve” 
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Figure 1.3.1.2.c. MGD screenshot of term details for “overriding aortic valve”, including synonyms, MP and Fyler 
ID, formal definition, and hierarchical depiction in MP browser 
 
B.2 LINE 1702 (MEGF8 AND CML5) 
B.2.1  ENU Database  
Appendix B.2.1, Figures 2.2.4.1.a-b,d include screenshots of mutant line 1702 as seen by 
researchers on the ENU database. 
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Figure 2.2.4.1.a. ENU database screenshot of summary defects, whole exome status, and mutant mice with 
genotype in line 1702 ([H] = homozygous; [h] = heterozygous) 
 
 
Figure 2.2.4.1.b.  ENU database screenshot of homozygous mutations recovered by WES for mutants 1702-003-2 
and 1702-007-1 as depicted on line 1702 page 
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Figure 2.2.4.1.d. Screenshot of images representing line 1702 phenotype in ENU database 
(organized by sample, phenotype, then modality) 
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B.2.2  MGD   
Appendix B.2.2, Figures 2.2.4.1.e-g include screenshots of line 1702 curated as Megf8b2b1702clo 
on MGD as seen by public 
 
 
Figure 2.2.4.1.e. MGD screenshot of Megf8b2b1702clo with mutation and phenotype annotation summarized under 
general line information 
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Figure 2.2.4.1.f. MGD screenshot of expanded view of phenotypes annotated to Megf8b2b1702clo  
according to MP ontology 
 
 
Figure 2.2.4.1.g. MGD screenshot of curated summative diagnosis and Fyler code data from ENU database for 
Megf8b2b1702clo 
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Figure 2.2.4.1.h. MGD screenshot of Human Disease and Mouse Model Detail for Carpenter Syndrome 2 with 
reference annotation to line Megf8b2b288clo   
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B.3 LINE 2407 (AN ADAMTS6 LINE) 
B.3.1  ENU Database  
Appendix B.3.1, Figures 2.2.4.2.b-d includes screenshots of mutant line 2407 as seen by 
researchers on the ENU database and spreadsheet from Adamts6 phenotype analysis.   
 
 
Figure 2.2.4.2.b.  ENU database screenshot of summary defects, whole exome status, and mutant mice with 
genotype in line 2407 ([H] = homozygous; [h] = heterozygous) 
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Figure 2.2.4.2.c.  ENU database screenshot of images representing line 2407 phenotype  
(organized by sample, phenotype, then modality) 
 
 
 
Figure 2.2.4.2.d. Statistical summary of observed phenotypes in Adamts6 lines by genotype [green = homozygous 
for Adamts6 mutation; blue = genotype unknown; red = included in final summative diagnosis] 
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B.3.2  MGD  
Appendix B.3.2, Figures 2.2.4.1.e-g include screenshots of line 2407 curated as Adamts6b2b2407clo 
on MGD as seen by the public. 
 
 
Figure 2.2.4.2.e. MGD screenshot of “Adamts6” query results [arrow = Adamts6b2b2407clo] 
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Figure 2.2.4.2.f. MGD screenshot of Adamts6b2b2407clo with mutation and phenotype annotation  
summarized under general line information 
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Figure 2.2.4.2.g. MGD screenshot of expanded view of phenotypes annotated to Adamts6b2b2407clo 
according to MP ontology 
 
 
Figure 2.2.4.2.h. MGD screenshot of curated summative diagnosis and Fyler code data from ENU database for 
Adamts6b2b2407clo 
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B.4 EFIC DEFECT CODES 
Appendix B.4, Table 2.2.1.2 represents the EFIC defect codes retrieved from the ENU database 
on 1 May 2014.  Duplicate entries (red), synonymous or ambigious terms (italicized), and 
spelling errors (blue) are highlighted below.  Entries are organized in the table based on the 
corresponding dialog box header on ENU database.   Defect codes were structured as a checklist. 
 
Table 2.2.1.2.  EFIC codes retrieved from ENU database on 1 May 2014 
EFIC Defect Codes (n = 182) 
Cardiovascular 
 Aberrant subclavian artery 
 Abnormal artery off MPA (remove) 
 Abnormal PA branching (remove) 
 Anomalous coronary venous return 
 Anomalous Muscle Band 
 Anomalous Muscle Band (remove) 
 Aortic Atresia 
 Aortic valve stenosis 
 Aortic valve stenosis 
 ASD 
 Atria Situs Ambiguus (remove) 
 Atypical trabeculation (remove) 
 AVSD 
 Coarctation of Aorta 
 Coarctation of Aorta 
 Common Atrium 
 Common AV valve 
 Cor triatriatum 
 Coronary artery fistula 
 Coronary artery high takeoff 
 Coronary defect (remove) 
 104 
 cystic atria walls 
 delayed OFT septation (remove) 
 Dextrocardia 
 Dextroversion 
 Dilated Atria (remove) 
 Dilated coronary artery 
 Dilated coronary vein 
 dilated pulmonary veins 
 Dilated Systemic Vein (IVC, SVC) 
 DORV 
 Double Aortic Arch 
 Double Aortic Arch with Vascular Ring (remove) 
 Double Descending Aorta (remove) 
 Hemiazygous venous connection 
 HLHS 
 HLHS Head Defect (remove) 
 HRHS 
 Hyertrophy (remove) 
 Hypertrophic Cardiomyopathy 
 Hypertrophic RV papillary muscle (remove) 
 Hypoplastic aortic arch 
 hypoplastic LV 
 Hypoplastic PA 
 Hypoplastic RV 
 Hypoplastic semilunar valve (remove) 
 Hypoplastic transverse aorta 
 Hypoplatic transverse aorta 
 Interrupted Aortic Arch 
 left atrial isomerism 
 Left Looped DA (remove) 
 left side aortic arch with abnormal heart position 
(remove) 
 LV diverticulum 
 LV hypertrophy (remove) 
 LV hypoplasia 
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 LV septum cavity 
 Malpositioning of OFT 
 MAPCA 
 Membranous VSD with outlet extension 
 Mesocardia 
 Mitral valve stenosis 
 Multiple VSDs 
 Muscular VSD 
 Muscular VSD 
 myocardiac hypertrophy 
 Noncompaction 
 Noncompaction of ventricular myocardium 
 Other type of Venticular septum defect 
 Outflow VSD 
 Outlet VSD committed to Ao 
 Overriding Aorta 
 Perimembranous VSD 
 perimembranous VSD 
 Preductal Aortic Coarctation (remove) 
 Pulmonary artersia 
 Pulmonary Atresia 
 pulmonary trunk stenosis 
 Retroaortic pulmonary trunk 
 Retroesophageal sling 
 Right aortic arch 
 Right aortic arch 
 Right atrial isomerism 
 Right atrial isomerism 
 Right PDA 
 RV Hypertrophy 
 RV myocardium abnormal 
 Secundum ASD 
 Septal Hypertrophy 
 Situs Inversus Totalis 
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 Small Ventricles 
 Spongy Ventricle walls 
 subaortic VSD 
 subpulmonary stenosis 
 Subpulmonary VSD 
 superior inferior ventricles 
 Taussig Bing type 
 Tetralogy of Flow (TOF) 
 Thickened Ao wall 
 Thickened atria wall 
 Thin wall LV 
 Thin wall RV 
 Total anomalous pulmonary venous return 
 Transposition of great arteries 
 Tricuspid Atresia 
 Truncus Arteriosus (PTA) 
 unbalanced AVSD 
 Vascular ring 
 vascular sling 
 Ventricular dilatation (LV) 
 Ventricular dilatation (RV) 
 Ventricular hypertrophy (biventricular) 
 Ventricular Hypertrophy (LV) 
 Ventricular Hypertrophy (RV) 
 ventricular septal hypertrophy 
 VSD 
 VSD (conus) 
 VSD (muscular) 
 VSD (perimembranous) 
 VSD committed to Ao 
 
Outflow Tract 
 D-TGA 
 DA stenosis 
 dilated aorta 
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 Dilated PT 
 DORV 
 Dual IVC 
 Hypoplastic PA 
 L-TGA 
 Malposition 
 Overriding Aorta 
 PA Hypoplasia 
 Patient Ductus 
 PTA 
 Pulmonary Atresia 
 Pulmonary stenosis 
 Right Looped DA 
 Right-Looped PTA 
 TGA 
 With Ductus 
  
Septation Defects 
 Common Atrium 
 Perimembranous VSD 
 pmVSD with outlet extension 
 Premature closeure of foramen ovale 
  
Valve Defects 
 Aortic atresia 
 Aortic valve abnormal 
 AVSD 
 AVSD 
 Mitral Valve Malformation 
 Pulmonary atresia membranous 
 Pulmonary Valve Abnormal 
 Quadricusp Truncal Valves 
 Semilunar Valve Abnormal 
 Semilunar valve Absent 
 Thickened AV valves 
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 Tricuspid Valve Hypoplasia 
 Tricuspid valve malformation 
  
Ventricle 
 Small RV 
  
Coronaries 
 Abnormal collateral 
 Abnormal origin 
 Coronary fistula 
 High Take Off 
 High Take Off Left Coronary 
 High Take Off Right Coronary 
 MAPCA 
  
Lung 
 Abnormal bronchi 
 cystic lungs 
 Dilated Bronchi 
 Hypoplastic Lung 
 Left Lung Isomerism 
 right isomerism lung 
 single lung lobe 
 Tracheal agenesis 
 Tracheoesophageal fistula 
  
Other Defects 
 Anencephaly 
 Azygous Continuation 
 Diverticulum 
 Double IVC 
 Esophagus abnormalities 
 Hemiazygous connection 
 Holoprosencaphly 
 Left Diaphragmatic Hernia 
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 left side IVC 
 Total Anomalous Pulmonary Venous Return 
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APPENDIX C 
ABBREVIATIONS AND ACRONYMS 
C.1 INSTITUTIONS 
Table C.1. Referenced institutions and the respective homepages 
Institution Abbreviation URL Homepage 
Jackson Laboratory JAX http://www.jax.org/ 
International Mouse Strain 
Resource 
IMSR http://www.findmice.org 
Mice Clinical and Research  
Services 
MCRS http://jaxmice.jax.org/index.html 
Mouse Genome Informatics MGI 
 Mouse Genome Database MGD http://www.informatics.jax.org 
Mouse Phenome Database MPD http://phenome.jax.org/ 
International Knockout Mouse  
Consortium 
IKMC http://www.knockoutmouse.org 
International Mouse Phenotyping  
Consortium 
IMPC https://www.mousephenotype.org/ 
National Institutes of Health NIH http://www.nih.gov/ 
cancer Biomedical Informatics  
Grid 
caBIG https://cabig.nci.nih.gov/ 
National Cancer Institute NCI http://www.cancer.gov/ 
National Center for Biotechnology  
Information 
NCBI http://www.ncbi.nlm.nih.gov/ 
National Heart, Lung, and Blood  
Institute 
NHLBI https://www.nhlbi.nih.gov/ 
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Bench to Bassinet Program B2B http://www.benchtobassinet.com/ 
Cardiovascular Development  
Consortium 
CvDC 
 
New England Research  
Institutes 
NERI http://www.neriscience.com/ 
Pediatric Cardiac Genomics  
Consortium 
PCGC 
 
Pediatric Heart Network PHN http://www.pediatricheartnetwork.org/ 
Online Mendelian Inheritance in  
Man 
OMIM http://www.omim.org/ 
U.S. National Library of Medicine NLM http://www.nlm.nih.gov/ 
University of California, Santa Cruz  
Genome Browser 
UCSC http://genome.ucsc.edu/ 
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C.2 CONGENITAL HEART DISEASE 
Table C.2.  Abbreviations of selected CHD diagnoses 
Diagnosis Abbreviation 
Congenital Heart Disease CHD 
Hypoplastic Left Heart Syndrome HLHS 
Inferior Vena Cava IVC 
Major Aortopulmonary Collateral Arteries MAPCA 
Supravalvular Aortic Stenosis SVAS 
Aortic Stenosis AS 
Pulmonary Stenosis PS 
Pulmonary Atresia PA 
Outflow Tract Malalignment OFT 
Double Outlet Right Ventricle DORV 
Patent Ductus Arteriosus PDA 
Persistent Truncus Arteriosus PTA 
Tetralogy of Fallot TOF 
Transposition of the Great Arteries TGA 
Septal Defects 
 Atrial Septal Defect ASD 
Atrioventricular Septal Defect AVSD 
Ventricular Septal Defect VSD 
Muscular Ventricular Septal Defect mVSD 
Perimembranous Ventricular Septal Defect pmVSD 
Total Anomalous Pulmonary Venous  
Return/Connection TAPVR/C 
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